Check for updates

OPEN ACCESS

EDITED BY Yi-Hung Chen, China Medical University, Taiwan

REVIEWED BY Paulo Sargento, Escola Superior de Saúde Ribeiro Sanches, Portugal Yajie Ji, Shanghai University of Traditional Chinese Medicine, China Xuancheng Zhou, Southwest Medical University, China

*CORRESPONDENCE Ying Zhang Zylzy501@163.com

RECEIVED 26 February 2025 ACCEPTED 24 June 2025 PUBLISHED 25 July 2025

CITATION

Wang Y, Sui B, Zhang Y, Fang L, Xie Y, Fang Y and Wang R (2025) Effect of acupuncture and moxibustion on the immune function of patients with malignant tumors: a systematic review and meta-analysis. *Front. Immunol.* 16:1583522. doi: 10.3389/fimmu.2025.1583522

COPYRIGHT

© 2025 Wang, Sui, Zhang, Fang, Xie, Fang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s)

and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Effect of acupuncture and moxibustion on the immune function of patients with malignant tumors: a systematic review and meta-analysis

Yan Wang¹, Bailu Sui^{1,2}, Ying Zhang^{1*}, Liyuan Fang¹, Yi Xie¹, Yuhang Fang^{1,2} and Runxi Wang¹

¹Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Graduate School, Beijing University of Chinese Medicine, Beijing, China

Background: Acupuncture and moxibustion have been shown to be safe and effective methods for bidirectional immunomodulatory function. Clinical practice and many studies have shown that acupuncture and moxibustion have a certain clinical effect on immune promotion in patients with malignant tumors.

Methods: Eight electronic databases were searched systematically for articles published through December 31, 2024. Study Selection Randomized controlled trial studies (RCTs) that reported The number of T lymphocytes cells in patients with malignant tumors who received acupuncture and/or moxibustionon treatment were included. For continuous variables, effect estimates were calculated as mean difference (MD); and for dichotomous variables, the risk ratio (RR) was calculated. A funnel plot was used to analyze potential publication bias.

Results: 33 studies involving 2610 participants were included. Patients who received acupuncture and/or moxibustion treatment had higher CD3⁺, CD4⁺, CD4⁺/CD8⁺ and natural killer (NK) cell levels, but lower CD8⁺ levels. At the same time, the anti-tumor treatment effect was better than that of the control group.

Conclusions: Evidence from this meta-analysis, acupuncture and moxibustion can enhance the immune function and improve the prognosis of malignant tumor patients. Further studies are recommended to support and confirm these findings.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023465759.

KEYWORDS

acupuncture, moxibustion, T lymphocyte cells, malignant tumors, meta-analysis

Introduction

According to Global Cancer Statistics 2020, there are 19.3 million new cancer cases and nearly 10 million cancer deaths estimatedly in worldwide, while the incidence and mortality of cancer are increasing year by year. It is estimated that by 2040, the global cancer burden will reach 28.4 million cases, an increase of 47% over 2020. The global situation of cancer prevention and control is grim (1). A weakened immune system leads to the development of tumors, and studies have shown that immune function is closely related to the prognosis of cancer (2). Recently, immunotherapy based on activating and enhancing the patient's immune system has shown anti-tumor effects (3). Immunotherapy mainly includes immune checkpoint inhibitors, tumor antigen vaccines, and immune stimulating cytokines (4). These treatment methods can reshape the tumor microenvironment, enhance the immune function, strengthen anti-tumor immune responses, and thus suppress tumor growth and recurrence (5).

However, there are still some limitations and challenges in the application of immunotherapy in cancer at present (6). For example, the effectiveness and sustainability of immunotherapy are still not ideal, and individual differences are large. Some patients have poor tolerance to immunotherapy (7). In addition, some patients may also experience immune-related adverse reactions during immunotherapy, which may affect the treatment effect (8).

Acupuncture and moxibustion demonstrate bidirectional immune modulation (9). In cancer, these therapies synergistically boost anti-tumor immunity through distinct mechanisms. Electroacupuncture enhances lymphocyte populations and granzyme B secretion while activating interferon-mediated signaling pathways (10). Moxibustion suppresses adrenalinedriven signaling to activate natural killer (NK) cell activity and limit tumor growth, while also reducing regulatory T cell (Treg) infiltration in the tumor microenvironment-a strategy that curtails immune evasion and tumor progression (11, 12). Clinical observations further support their role in improving cancer patients' immune function and prognosis, such as acupuncture at ST36 increasing NK cell counts and reducing tumor burden in cervical cancer (13, 14). Together, these findings underscore the capacity of acupuncture and moxibustion to reprogram immune responses, tipping the balance toward anti-tumor surveillance while mitigating immune dysregulation.

There is still a lack of systematic reviews of the effect of acupuncture and moxibustion on the immunity of patients with malignant tumors. This study aims to demonstrate and quantify the effect of acupuncture and moxibustion on the immune function of patients with malignant tumors, especially the number of T lymphocyte subsets, and to analyze the improvement of prognosis and quality of life of patients with malignant tumors.

Methods

This systematic review and meta-analysis was performed according to the guideline of Preferred Reporting Items for

Systematic review and Meta-Analysis Protocols (PRISMA-P) 2015 (15). Procedures and study inclusion criteria were registered in PROSPERO (CRD42023465759) (https://www.crd.york.ac.uk/prospero/).

Data sources and search strategy

A systematic search for articles published in electronic databases (PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, Wanfang database, VIP database and Chinese BioMedical Literature database) through December 31, 2024, was performed with no language or time restrictions. Medical subject headings (MeSH) terms and free text terms were used to obtain more comprehensive studies. The MeSH terms of "Acupuncture", "Electroacupuncture", "Moxibustion", "Neoplasms", "cancer", "Immunity", "T-Lymphocytes" were used to construct search Electroneedle, fire needle.

Eligible criteria

Inclusion criteria


- The patients diagnosed with solid malignant tumor by histopathology;
- 2. Only RCTs were included;
- 3. The control group received conventional therapies (e.g., chemoradiotherapy, radiotherapy, surgical treatment, traditional Chinese Medicine (TCM) treatment), and intervention groups received what control groups received plus acupuncture (including electroacupuncture, fire needle et.al) and/or moxibustion treatment;
- The outcomes included immune function index (e.g., CD3⁺, CD4⁺, CD8⁺ or CD4⁺/CD8⁺).

Exclusion criteria

- 1. Repeated publication;
- 2. Outcome of interest not included;
- 3. Original data cannot be obtained by contacting the original author.

Study selection and data extraction

EndNote 21 was used to manage literature. Two researchers (YW and BLS) independently retrieved the titles and abstracts of all articles. Any disagreement in screening process should be consulted with another researchers (YZ) to make a decision. The relevant information were independently extracted and cross-checked by two researcher (YW and BLS) independently, which including: 1) basic information of the article: author's name, year of publication, study type, and sample size; 2) patient characteristics: age, gender, cancer typology, pathological types and disease stage; and 3) treatment



outcomes: clinical intervention, main points of acupuncture and/or moxibustionon, number of intervention, duration of intervention, and outcomes. Disagreements were solved by discussion or consulting third-party opinion (YZ). Imputing a change-frombaseline standard deviation (SD) and mean using a correlation coefficient. A SD of the change from baseline for the experimental intervention was input, using following formula:

$$SD_{E, change} = \sqrt{[SD_{E, baseline}^{2} + SD_{E, final}^{2} - (2 \times Corr \times SD_{E, baseline} \times SD_{E, final})]}; Corr = 0.75$$
(16)

Mean value of the change from baseline for the experimental intervention was input, using:

$$Mean_{E, change} = Mean_{E, final} - Mean_{E, baseline}$$
 (17)

All data were rounded to two decimal places.

Outcomes of interest

The primary outcome of this study was immune function, mainly evaluated with the number of T lymphocyte subsets, including $CD3^+$, $CD4^+$, $CD8^+$ or $CD4^+/CD8^+$. The secondary outcomes included the number of NK cell and clinical effective rate. The clinical effective rate = complete response (CR) + partial response(PR). CR and PR were defined by Response Evaluation Criteria in Solid Tumors (RECIST).

Assessment of study quality

Two researchers (YW and BLS) used the Cochrane Risk of Bias Tool (RoB) (18) to evaluate the methodological quality of all

included RCTs independently. The following seven domains were assessed: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases. The included RCTs were assessed as low, uncertain, or high risk of bias. The results were shown in RoB graph.

Statistical analysis

Review Manager software (version 5.4.1) was used to perform the meta-analysis. The random-effect model were used to synthesize evidence. Sensitivity or subgroup analysis were conducted to determine the cause of heterogeneity if it exists. The method of deleting studies one by one needed to be used to perform sensitivity analysis of the results to ensure stability. The subgroup analysis of the meta-analysis results for each outcome was required. The subgroup only includes items related to the comparison. Subgroup analysis was performed based on cancer typology and clinical interventions. For continuous variables, effect estimates were calculated as mean difference (MD); and for dichotomous variables, risk ratio (RR) were calculated. The effect estimates with their 95% confidence intervals (CI) were presented in the forest plots. If meta-analysis was not suitable, descriptive analysis was performed. Funnel plot was used to analyze potential publication bias. P < 0.05 was considered statistically significant.

Results

A total of 2610 articles were obtained by searching the database. There were 779 duplicate literature were found. After reading the title and abstract, 1582 articles were excluded. Then, after strict

TABLE 1 Study characteristics of included studies.

Study ID	Sample size (I/C)	Age (ye	ear) (I/C)	Canc	er typology (I/C)	Clinical int	ervention (I/C)	Main point(s)	Duration of intervention	Outcon
Chen 2004 (19)	28/28	46.2	49	Nasopharyngeal cancer: n=11; NSCLC: n=17	Nasopharyngeal cancer: n=13; NSCLC: n=15	Electroacupuncture	Chemotherapy: CFP for nasopharyngeal cancer; VP for NSCLC	Zusanli (ST36)	42 days	2300
Chen 2008 (22)	30/30	62.07	60.8	NSCLC	NSCLC	Acupuncture	Chemotherapy and TCM treatment	Feishu (BL13); Zhongfu (LU13); Taiyuan (LU9); Fengmen (BL12); Xinshu (BL15); Gaohuangshu (BL43); Chize (LU5); Danzhong (RN17); Dazong; Tender point	42 days	03
Chen 2016 (20)	30/30	50.9 ± 10.90	51.2 ± 7.63	Breast cancer	Breast cancer	Acupuncture	Chemotherapy and symptomatic supportive treatment	Neiguan (PC6); Shenmen (HT7); Guanyuan (RN4); Xuanzhong (GB39); Sanyinjiao (SP6); Zusanli (ST36); Xuehai (SP10);	24 days	233
Chen 2018 (21)	20/20	54.5 ± 4.6	55.7 ± 4.3	Breast cancer	Breast cancer	Electroacupuncture	Radical mastectomy for breast cancer and general anesthesia	Neiguan (PC6); Sanyinjiao (SP6); Hegu (LI4); Zusanli (ST36)	4 days	234
Guo 2013 (23)	30/30	52.50 ± 13.21	49.17 ± 11.33	Gastric cancer	Gastric cancer	Acupuncture	Chemotherapy (DFP)	Zhongwan (CV12); Guanyuan (RN4); Neiguan (PC6); Zusanli (ST36)	42 days	236
Jiang 2020 (24)	44/45	49.62 ± 6.51	50.19 ± 6.82	Nasopharyngeal cancer	Nasopharyngeal cancer	Acupuncture	Radiotherapy 35 times and chemotherapy 3 times (DDP)	Tiantu (CV22); Renying (ST9); Guanyuan (RN4); Qihai (CV6)	49 days	200
Li 2009 (25)	30/30	64.10 ± 11.16	59.16 ± 12.87	Lung cancer: n=9; Intestinal cancer: n=7; Hepatocellular carcinoma: n=8; Gastric cancer: n=4; Breast cancer: n=2	Lung cancer: n=8; Intestinal cancer: n=8; Hepatocellular carcinoma: n=8; Gastric cancer: n=3; Breast cancer: n=3	Moxibustionon	Chemotherapy	Gaohuangshu (BL43); Pishu (BL20); Weishu (BL21); Geshu (BL17); Shenshu (BL23)	14 days	233
Li 2020 (26)	32/32	65.12 ± 5.18	65.85 ± 5.02	NSCLC	NSCLC	Acupuncture and moxibustionon	Chemotherapy (AP)	Zusanli (ST36); Qihai (CV6)	84 days	233
Liao 2018 (27)	29/30	48.72 ± 1.23	48.80 ± 1.31	Lung cancer: n=20; Intestinal cancer: n=3; Gastric cancer: n=3; Breast cancer: n=2; Cervical cancer: n=1	Lung cancer: n=17; Intestinal cancer: n=2; Gastric cancer: n=2; Endometrial cancer: n=2; Nasopharyngeal cancer: n=2; Ovarian cancer:n=3; Cervical cancer: n=1; Thymoma: n=1	Acupuncture	Chemotherapy (Platinum-containing)	Zusanli (ST36); Zhigou (TE6); Taichong (LR3); Taibai (SP3); Xinmen; Xiaotianxin	10 days	233
Liu 2022 (<mark>28</mark>)	30/30	55.10 ± 9.52	55.57 ± 9.12	Lung cancer: n=11; Gastric cancer: n=7; Ovarian cancer:	Lung cancer: n=10; Gastric cancer: n=5; Ovarian cancer:	Acupuncture and moxibustionon	Chemotherapy and symptomatic treatment	Shenshu (BL23); Pishu (BL20); Ganshu (BL18)	10 days	023

Frontiers in Immunology

Study ID	Sample size (I/C)	Age (ye	ear) (I/C)	Canc	er typology (I/C)	Clinical inte	ervention (I/C)	Main point(s)	Duration of intervention	Outcom
				n=4; Colorectal cancer: n=6; Other: n=2	n=5; Colorectal cancer: n=7; Other tumors: n=3					
	30/30	57.57 ± 8.90	58.23 ± 8.16	Lung cancer: n=10; Gastric cancer: n=4; Ovarian cancer: n=3; Colorectal cancer: n=9; Other tumors: n=4	Lung cancer: n=12; Gastric cancer: n=2; Ovarian cancer: n=2; Colorectal cancer: n=10; Other tumors: n=4	Acupuncture and moxibustionon	Chemotherapy and interleukin-11	Shenshu (BL23); Pishu (BL20); Ganshu (BL18)	10 days	-
Mao 2022 (29)	17/16	65.41 ± 11.56	67.94 ± 10.08	NSCLC	NSCLC	Moxibustionon	Pembrolizumab, pemetrexed, Bevacizumab (1 or more)	Zusanli (ST36)	21 days	23
Pan 2013 (30)	31/30	57	58	Gastric cancer	Gastric cancer	Moxibustionon	TCM treatment	Zusanli (ST36)	6 months	233
Pei 2016 (31)	30/30	58.90 ± 8.73	63.00 ± 8.51	NSCLC	NSCLC	Fire acupuncture	Chemotherapy (TP/ GP/DP/NP)	Geshu (BL17); Danshu (BL19)	21 days	233
Qin 2012 (32)	15/15	N	N	Gastric cancer: n=3; Intestinal cancer: n=6; Lung cancer: n=1; Ovarian cancer: n=2; Liver cancer: n=3	Gastric cancer: n=4; Intestinal cancer: n=7; Lung cancer: n=2; Ovarian cancer: n=1; Liver cancer: n=2	Moxibustionon	Symptomatic treatment (including TCM treatment)	Shenque (RN8); Guanyuan (RN4); Zhongwan (CV12); Qihai (CV6); Tianshu (ST25); Zusanli (ST36); Yongquan (KI1)	14 days	2340
Wang 2016 (33)	70/70	60.57 ± 5.33	60.84 ± 5.41	NSCLC	NSCLC	Electroacupuncture	Chemotherapy (GP)	Zusanli (ST36); Sanyinjiao (SP6)	21 days	233
Wang 2023 (34)	30/30	62.43 ± 7.62	60.81 ± 6.77	NSCLC	NSCLC	Acupuncture and moxibustionon	Chemotherapy (TP/ GP/AP)	Qihai (CV6); Guanyuan (RN4); Zusanli (ST36); Pishu (BL20); Shenshu (BL23)	21 days	233
Wu 2016 (35)	20/20	62.04 ± 7.783	64.40 ± 8.829	Esophageal cancer	Esophageal cancer	Moxibustionon	N	Feishu (BL13); Gaohuangshu (BL43); Zusanli (ST36)	42–49 days	023
Wu 2021 (36)	41/41	48.72 ± 4.16	49.01 ± 4.14	Breast cancer: n=9; Lung cancer: n=14; Gastric cancer: n=12; Liver cancer: n=3; Other tumors: n=3;	Breast cancer: n=8; Lung cancer: n=15; Gastric cancer: n=10; Liver cancer: n=5; Other tumors: n=3	Acupuncture and moxibustionon	Symptomatic treatment	Zusanli (ST36); Sanyinjiao (SP6)	14 days	24
Wu 2022 (37)	50/50	50.78 ± 7.32	50.85 ± 7.24	NSCLC	NSCLC	Acupuncture and moxibustionon	Chemotherapy (TP)	Xuehai (SP10); Waiguan (SI4); Taichong (LR3)	14 days	02
Xiang 2022 (38)	34/34	57.30 ± 8.26	57.25 ± 8.22	Gastric cancer: n=12; Rectal cancer:	Gastric cancer: n=13; Rectal cancer: n=10; Colon cancer: n=11	Acupuncture and moxibustionon	TCM treatment	Zusanli (ST36); Qihai (CV6)	14 days	233

TABLE 1 Continued

Study ID	Sample size (I/C)	Age (ye	ar) (I/C)	Cance	er typology (I/C)	Clinical int	ervention (I/C)	Main point(s)	Duration of intervention	Outcome
				n=11; Colon cancer: n=11						
Xing 2022 (39)	29/29	68.48 ± 5,37	69.45 ± 5,89	Gastric cancer	Gastric cancer	Electroacupuncture	Surgery with transversus abdo minis plane block anesthesia	Hegu (LI4); Neiguan (PC6); Zusanli (ST36)	1 days	234
Xiong 2017 (40)	38/38	65.43 ± 7.86	65.57 ± 7.91	Liver cancer	Liver cancer	Acupuncture	Hepatic Chemoembolization (floxuridine, epirubicin and hydroxycamptothecin)	Baihui (GV20); Neiguan (PC6); Sanyinjiao (SP6); Weiqu (in head skin point)	5 days	2343
Xu 2012 (41)	30/30	61.57 ± 6.53	61.63 ± 6.55	NSCLC	NSCLC	Fire acupuncture	Chemotherapy (TP/GP)	Geshu (BL17); Danshu (BL19)	7 days	230
Xu 2024 (42)	30/30	51.60 ± 9.45	50.73 ± 9.18	Cervical cancer	Cervical cancer	Acupuncture	Radiotherapy and chemotherapy 5 times (DDP)	Guanyuan (RN4); Qihai (CV6)	35 days	2346
Xue 2013 (43)	32/32	57.4	± 6.6	Gastric cancer	Gastric cancer	Moxibustionon	Conventional nursing and TCM treatment	Zusanli (ST36)	6 months	033
Yang 2021 (44)	33/32	54.38 ± 8.97	54.38 ± 8.97	Colorectal cancer	Colorectal cancer	Acupuncture and moxibustionon	Symptomatic supportive treatment	Guanyuan (RN4); Qihai (CV6); Tianshu (ST25); Taixi (KI3); Zusanli (ST36)	28 days	2343
Zhang 2011 (45)	35/35	57.1 ± 11.7	59.1 ± 8.5	Colorectal cancer	Colorectal cancer	Acupuncture and moxibustionon	Postoperative routine treatment	Zusanli (ST36); Shangjuxu (ST37); Xiajuxu (ST39); Sanyinjiao (SP6); Yinlingquan (SP9)	10 days	243
Zhang 2017 (46)	30/30	57.27 ± 5.38	57.32 ± 5.36	NSCLC	NSCLC	Moxibustionon	Chemotherapy (GP)	Zusanli (ST36); Guanyuan (RN4); Qihai (CV6); Feishu (BL13); Shenshu (BL23); Pishu (BL20); Gaohuangshu (BL43)	21 days	2396
Zhang 2021 (47)	66/66	50.77 ± 3.19	51.02 ± 2.48	NSCLC	NSCLC	Acupuncture and moxibustionon	Conventional nursing	Sanyinjiao (SP6); Guanyuan (RN4); Zusanli (ST36); Hegu (LI4)	30 days	12
Zhao 2022 (48)	34/34	47.13 ± 4.06	45.47 ± 4.70	NSCLC	NSCLC	Acupuncture and moxibustionon	Chemotherapy (Taxol and Platinum)and TCM treatment	Zusanli (ST36); Zhongwan (CV12); Danzhong (RN17); Qihai (CV6)	21 days	2336
Zhao 2023 (49)	32/33	64.25 ± 7.81	64.27 ± 9.65	Lung Cancer	Lung Cancer	Acupuncture	Symptomatic treatment	Danzhong (RN17); Zhongwan (CV12); Qihai (CV6); Zusanli (ST36); Xuehai (SP10); Waiguan (SI4)	N	030
L				1			1			(Continue

(Continued)

10.3389/fimmu.2025.1583522

literature screening and reading the full-text articles according to the inclusion and exclusion criteria, 216 articles were eliminated as follows: 38 did not RCTs, 78 did not meet the inclusion criteria, 46 studies lack of outcome measures, 37 had incomplete data, thirteen articles were published in duplicate and four were non-solid tumors. Finally, a total of 33 eligible trials were included. The specific retrieval process is shown in Figure 1.

Study characteristics

Thirty-three RCTs were included with 2259 participants that divided into two groups that control group received conventional therapies (n=1130), and intervention groups received what control groups received plus acupuncture and/or moxibustion treatment (n=1129), including acupuncture, electroacupuncture, fire acupuncture and moxibustionon (19-51). Study characteristics of included studies was shown in Table 1. In participant, the average age of patients of the 33 studies were between 45 and 70 years old. There were 12 studies with lung cancer (20, 26, 29, 31, 33, 34, 37, 41, 46-49) and seven studies with gastrointestinal cancer (23, 30, 38, 39, 43-45). Nineteen studies used chemotherapy (19-28, 31, 33, 34, 37, 40-42, 46, 48), of which two studies combined with radiotherapy (24, 42) and two studies combined with TCM (20, 48). One study may have used one or more of the following: immunotherapy, targeted therapy, or chemotherapy (29). Eleven studies used acupuncture and moxibustion simultaneously (26, 28, 34, 36-38, 44, 45, 47, 48, 50). Fourteen studies used acupuncture only (19-24, 27, 31, 33, 39-42, 49), of which four studies used electroacupuncture (19, 22, 33, 39), two studies used fire acupuncture (31, 41). Moxibustion was used only in eight studies (25, 29, 30, 32, 35, 43, 46, 50). The most frequently used acupoints were: Zusanli (ST36), Qihai (CV6), Guanyuan (RN4), and Sanyinjiao (SP6). Study characteristics of included studies in Table 1.


Methodological quality of included studies

Twenty-seven RCTs were assessed as low risk for random sequence (21, 22, 24-34, 37-42, 44-51), including 24 RCTs used the random number table method (22, 24-32, 34, 37-40, 42, 44-51), one RCT used the simple randomization (41), two RCTs used the block randomization (21, 33) and the other six RCTs did not elaborate on specific methods of randomization (19, 20, 23, 35, 36, 43), so the risks were unclear. Due to the particularness of acupuncture and moxibustion, it is difficult to blind the practitioners of acupuncture and moxibustion. One study mentioned the blinding of researchers and patients (39), one study mentioned the blinding of statisticians and examiners (31), and one study mentioned the separation of researchers, data collection, and data statistical analysis (49), which considered low risk of bias. Three of the included studies achieved concealment by using sealed envelopes and were deemed to be at low risk of bias, which resulted in a low risk of bias in relative fields (28, 29, 39). None of the 33 studies had missing data or missing data that were

Study ID	Sample size (I/C)	Age (ye	Age (year) (I/C)	Cance	Cancer typology (I/C)	Clinical inte	Clinical intervention (I/C)	Main point(s)	Duration of intervention	Outcome
Zhou 2019 (50)	30/30	67 ± 8	6 3 ± 11	Lung cancer: n=7; Digestive system tumors: n=15; Gynecological tumors: n=5; Other tumors: n=2	Lung cancer. n=12; Digestive system tumors: n=11; Gynecological tumors. n=2	Moxibustionon	Comprehensive treatment of traditional Chinese and western medicine	Zusanli (ST36)	12 days	@ @
Zhu 2023 (51)	40/40	46.18 ± 10.13	45.70 ± 10.07	gastric cancer: n=16; Cervical cancer: n=10; Rectal cancer: n=8; Colon cancer: n=6	gastric cancer: n=18; Cervical cancer: n=8; Rectal cancer: n=7; Colon cancer: n=7	Acupuncture and moxibustionon	Gastrointestinal decompression	Zhongwan (CV12); Xiawan; Shangjuxu (ST37); Xiajuxu (ST39); Tianshu (ST25); Sanyinjiao (SP6); Zusanli (ST36)	Until 1 week after the patient's intestinal obstruction improved	0
tervention group: Pemetrexed and 33+; @CD4+; @C	; C, Control group; N Cisplatin; TCM, Tra :D8+; @CD4+/CD8+;	I, Intervention group: C, Control group: NSCLC, Non-small Cell Lung Cancer; I AP, Pemetrexed and Gisplatin; TCM, Traditional Chinese Medicine; N, None. @CD3+; @CD4+; @CD8+; @CD4+/CD8+; @NK; @clinical efficacy:	ell Lung Cancer; DDP, dicine; N, None. acy.	Cisplatin; C, Cyclophos	Lintervention group; C, Control group; NSCLC, Non-small Cell Lung Cancer; DDP, Gisplatin; C, Cyclophosphamide; F, 5 fluorouracil; V, Etoposide; TP, Taxol and Cisplatin; GP, Gemcitabine and Cisplatin; DP, Docetaxel and Cisplatin; NP, Vinorelbine and Cisplatin; AP, Pemetrexed and Gisplatin; TCM, Traditional Chinese Medicine; N, None.	poside; TP, Taxol and	Cisplatin; GP, Gemcitab	ine and Cisplatin; DP, Docetaxe	l and Cisplatin; NP, Vinorelbine a	nd Cisplatin;

TABLE 1

Continued



comparable in each intervention group, and the reasons for missing data were similar, so they were rated as having a low attrition risk of bias. All 33 studies had a low risk of reporting bias. The quality assessment of the included trials risk of bias graph in Figure 2.

Meta-analysis results

CD3⁺

All the included RCTs reported the CD3+ T lymphocyte counts of the patients. Meta-analysis results showed that: effect of the intervention group was significantly better than that of the control group in improving the CD3+ (MD = 4.97, 95% CI 3.81 to 6.13). Further subgroup analysis was conducted according to cancer typology, two groups clinical intervention (including combined chemotherapy, surgery, and other therapies), acupoint selection (according to whether the use of Zusanli (ST36) acupoint is divided), intervention group clinical treatment (according to the use of acupuncture, moxibustion, acupuncture and moxibustion divided) and duration of treatment (according to treatment duration of 30 days or more and less than 30 days divided). Subgroup analysis showed no statistical difference in cancer typology (P=1.00), control group clinical intervention (P=0.16), acupoint selection (P=0.64) and duration of treatment (P=0.53). The forest plot was shown in Supplementary Materials. (Supplementary Figures S1-S4).

The subgroup analysis revealed that the intervention group clinical treatment (P = 0.03) were the main source of heterogeneity

in CD3⁺ and the forest plot was shown in Figure 3. No source of heterogeneity was identified by sensitivity analysis.

CD4⁺

A total of 33 studies (19–51) analyzed the effects of CD4⁺. The results showed that the intervention group had a more significant effect on increasing the CD4⁺ (MD = 4.25, 95% CI 2.80 to 5.69). Further subgroup analysis was conducted. It is shown that there is no statistical difference in cancer typology (P=0.23), two groups clinical intervention (P=0.80), acupoint selection (P=0.40) and duration of treatment (P=0.39). The forest plot was shown in Supplementary Materials. (Supplementary Figures S5–S8).

Similarly, the subgroup analysis revealed that the intervention group clinical treatment (P = 0.0001) were the main source of heterogeneity in $CD4^+$. Forest plot was shown in Figure 4. No source of heterogeneity was identified by sensitivity analysis.

CD8⁺

26 RCTs with 1673 patients reported CD8⁺ index (19–23, 25–28, 30–35, 38–43, 45, 46, 48–50). Meta-analysis showed that the intervention group was decreased compared with the control group in CD8⁺ (MD = -1.56 95% CI -3.09--0.03). The results are presented in Figure 5.

No sources of heterogeneity were identified by subgroup analysis in the intervention group clinical treatment (P = 0.07), cancer typology (P=0.37), two groups clinical intervention (P=0.48), acupoint selection (P=0.72) and duration of treatment (P=0.45). (Supplementary Figures S9–S13).

		eriment			ontrol	-		Mean Difference	Mean Difference
Study or Subgroup 1.1.1 Acupuncture	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Chen 2004	1	3.77	28	1.4	6.19	28	3.1%	-0.40 [-3.08, 2.28]	
Chen 2004	0.25	6.13	30	-7.64	6.6	30	2.9%	7.89 [4.67, 11.11]	
Chen 2016	9.59	4.16	30	0.71	4.99	30	3.2%	8.88 [6.56, 11.20]	
Chen 2018	-2.1	3.38		-2.98	3.45	20	3.2%		
		3.83				30		0.88 [-1.24, 3.00]	
Guo 2013	1.8			-1.67	3.54		3.4%	3.47 [1.60, 5.34]	
Jiang 2020	-5.64	5.25		-16.3	4.96	44	3.3%	10.66 [8.53, 12.79]	
Liao 2018		8.74	29	5.17	8.93	29	2.3%	7.66 [3.11, 12.21]	
Pei 2016	3.46	3.81	30	0.4	4.32	30	3.3%	3.06 [1.00, 5.12]	
Wang 2016	12.07	5.93		1.09	4.63	70	3.4%	10.98 [9.22, 12.74]	
Xing 2022	-0.6	4.57		-4.27	3.95	29	3.2%	3.67 [1.47, 5.87]	
Xiong 2017	0.43	6.25	38	-3.91	6.61	38	3.0%	4.34 [1.45, 7.23]	
(u 2012	0.07	7.21	30	-6.37	8.05	30	2.6%	6.44 [2.57, 10.31]	
Ku 2024	20.64			11.21	7.32	30	2.6%	9.43 [5.45, 13.41]	
Zhao 2023	2.72	5.04	32	-1.33	7.94	33	2.9%	4.05 [0.83, 7.27]	
Subtotal (95% CI)			470			471	42.3%	5.73 [3.64, 7.82]	-
Heterogeneity: Tau ²					(P < 0.0	0001);	I ² = 90%		
Test for overall effect	t: Z = 5.36	(P < 0.	00001)					
1.1.2 Moxibustion									
Li 2009	-1.86	3.88	30	-2.26	3.43	30	3.4%	0.40 [-1.45, 2.25]	
Mao 2022	-1.93	6.05	17	2.98	6.71	16	2.4%	-4.91 [-9.28, -0.54]	
Pan 2013	2.24	5.08	31	1.13	5.35	30	3.1%	1.11 [-1.51, 3.73]	
Qin 2012		11.4		-1.17	11.4	15	1.3%	2.09 [-6.07, 10.25]	
Wu 2016	7.11	9.1	20	5.31	10.12	20	1.9%	1.80 [-4.16, 7.76]	
Kue 2013	3.39	5.25	32	0.69	5.32	32	3.1%	2.70 [0.11, 5.29]	——————————————————————————————————————
Zhang 2017	19.11	6.7	30	10.46	3.17	30	3.1%	8.65 [6.00, 11.30]	
Zhou 2019	1.93	9.2	30	0.43	8.56	30	2.4%	1.50 [-3.00, 6.00]	
Subtotal (95% CI)			205			203	20.6%	1.80 [-0.93, 4.54]	
Heterogeneity: Tau ²	= 11.36: C	chi² = 37	7.38, d	f = 7 (P	< 0.000	01); l² =			
Test for overall effect									
1.1.3 Acupuncture a	and moxil	oustion							
Li 2020	3.74			-0.82	4.33	32	3.2%	4.56 [2.26, 6.86]	
Liu 2022		9.65	32	-0.82	7.99	30	2.4%	4.93 [0.45, 9.41]	
Liu 2022	6.69	6.97	30	1.32	7.21	30	2.4%	5.37 [1.78, 8.96]	
Wang 2023	3.61	5.03	30		3.62	30	3.2%	3.39 [1.17, 5.61]	
Wang 2023 Wu 2021	14.3	4.43	41		3.85	41	3.4%	5.92 [4.12, 7.72]	
Wu 2021 Wu 2022				0.30 17.01	3.85	50	3.4%	3.04 [1.73, 4.35]	
Xiang 2022		3.39 4.58	50 34	5.67	3.27 4.54	50 34	3.5%	4.59 [2.42, 6.76]	
Yang 2022 Yang 2021	9.99	4.56 4.57	33	0.12	3.62	34	3.3%		
		4.57 7.15	33	2.79	3.62 6.22	32	3.3% 2.9%	9.87 [7.87, 11.87]	
Zhang 2011								10.47 [7.33, 13.61]	-
Zhang 2021	7.79	2.22	66	4.63	2.55	66	3.6%	3.16 [2.34, 3.98]	
Zhao 2022		8.12	34	3.93	8.04	34	2.6%	8.67 [4.83, 12.51]	
Zhu 2023	16.9	6.28	40	9.12	6.07	40	3.1%	7.78 [5.07, 10.49]	▲
Subtotal (95% CI)		12 70	455	44.00	. 0.000	454	37.1%	5.81 [4.31, 7.31]	-
Heterogeneity: Tau ² Test for overall effect					< 0.000	UT); I ² =	- 04%		
				,					
Total (95% CI)			1130				100.0%	4.97 [3.81, 6.13]	
Heterogeneity: Tau ²					> < 0.00	001); l²	= 88%		-10 -5 0 5 10
Test for overall effect									Favours [control] Favours [experimental]
		Chi2 - 6	5 70 d	f = 2 (P)	= 0.03	$l^2 = 70$	5%		. arous foundal in arous forbeimental
Test for subaroup dif	ferences:	011 - 0	J.1 J. u		0.007		.0 /0		
	terences:	0111 - 0	J.1 J. U	2.11	0.001		.070		

CD4⁺/CD8⁺

21 RCTs involving 670 cases in the intervention group and 670 cases in the control group reported $CD4^+/CD8^+$ in the outcome indicators (19, 22–24, 26–28, 32, 34–36, 38–42, 44–46, 49, 50). Meta-analysis showed that compared to control groups, intervention groups were significantly better in increasing the level of $CD4^+/CD8^+$ (MD = 0.29 95% CI 0.20–0.38). Subgroup analysis showed that the heterogeneity was associated with the cancer typology (P<0.00001). The results are presented in Figure 6.

No sources of heterogeneity were identified by subgroup analysis in the intervention group clinical treatment (P = 0.31), two groups clinical intervention (P=0.85), acupoint selection (P=0.63) and duration of treatment (P=0.65). (Supplementary Figures S14–S17).

NК


15 RCTs with 963 patients reported NK index (19, 21, 22, 25, 29-33, 40, 43-45, 48, 51). Meta-analysis showed that the

intervention group was greatly improved compared with the control group in increasing NK (MD = 4.75, 95% CI 1.56–7.94). Subgroup analysis showed that the heterogeneity was associated with the cancer typology (P<0.0001) and two groups clinical intervention (P=0.0006). The results are presented in Figures 7, 8.

No sources of heterogeneity were identified by subgroup analysis in the intervention group clinical treatment (P = 0.21), acupoint selection (P=0.94) and duration of treatment (P=0.34). (Supplementary Figure S18–S20).

Clinical effective rate

Five RCTs with 337 patients reported clinical efficacy in outcome indicators (24, 31, 42, 46, 48). The results showed that compared to the patients who received conventional therapies, those who received acupuncture and moxibustion plus conventional therapies have a significantly better clinical efficacy (RR = 1.32, 95% CI 1.16–1.52). The forest plot is shown in Figure 9.



Publication bias

The funnel plot of the primary outcome (CD3⁺, CD4⁺) displayed an uneven distribution of studies, suggesting presence of publication bias. The result is presented in Figures 10, 11. The publication bias may be associated with negative results not being published and a part of studies had small sample sizes.

Discussion

The results showed that combined acupuncture and moxibustion, the levels of $CD3^+$, $CD4^+$, $CD4^+/CD8^+$, and NK cells increased, while the level of $CD8^+$ cells decreased. Additionally, acupuncture and moxibustion indicated a positive effect on short-term clinical outcomes.

T lymphocytes cells are an important component of the immune system and are the main cellular component of the adaptive immune system, playing a crucial role in resisting pathogen invasion and suppressing tumorigenesis (52). A large number of studies have shown that T lymphocytes in the tumor microenvironment play an important role in the anti-tumor response. High levels of tumor-infiltrating T cells usually indicate a better prognosis for patients (53-55). CD3+ can effectively reflect the levels of CD4⁺ and CD8⁺. CD4⁺ directly reflects the immune function of the patient (56). CD8⁺ participates in the process of transmitting activation signals from T lymphocyte receptors recognizing antigens, and it belongs to cytotoxic T lymphocytes. CD8⁺ can produce negative regulation on T lymphocyte and B lymphocyte function through its own and related cytokines, inhibiting the formation of cellular immunity and antibodies, and its increased level can aggravate the immune dysregulation (57). CD4⁺/CD8⁺ balance is a key factor in maintaining the immune response (58). NK cells are an important component of tumor immune surveillance and play an important role in preventing tumor growth (59).

However, it has been proven that $CD8^+$ T lymphocytes are associated with poor prognosis in cancer patients. As the tumor grows and develops, it can stimulate and induce the proliferation of $CD8^+$ T lymphocytes, and the increase of $CD8^+$ T lymphocytes can

Study of Subgroup Mean SD Total Weight IV. Random, 95% CI IV. Random, 95% CI Chen 2004 0.4 2.69 28 7.4 2.72 28 3.9% -7.00 [-8.42, -5.6] Chen 2006 0.43 4.25 30 0.54 4.71 30 3.7% 0.97 [-1.30, 3.24] Chen 2016 5.97 7.23 30 2.44 3.63 30 3.5% 3.56 [0.67, 6.45] Ghen 2018 -0.02 2.48 20 0.11 1.56 20 4.0% -0.13 [-1.41, 1.15] Guo 2013 -6.04 6.17 30 -1.36 6.38 30 3.5% -4.68 [-7.86, -1.50] Li 2009 -1.97 2.41 32 0.07 2.52 2.0% -1.90 [-3.11, -0.69] Liao 2018 4.27 6.97 29 2.21 6.63 29 3.4% 2.06 [-1.40, 2.64] Liu 2022 -0.18 4.02 30 -0.52 3.53 3.3% 0.07 [-1.81, 1.95]	
Chen 2008 0.43 4.25 30 -0.54 4.71 30 3.7% 0.97 [-1.30, 3.24] Chen 2016 5.97 7.23 30 2.41 3.63 30 3.5% 3.56 (0.67, 6.45) Chen 2018 -0.02 2.48 20 11 1.56 20 4.0% -0.13 [-1.41, 1.5] Guo 2013 -6.04 6.17 30 -1.36 6.38 30 3.5% -4.68 [-7.86, -1.50] Li 2009 -1.31 5.45 30 -3.9 7.17 30 3.6% 2.56 [-1.0, 5.28] Li 2020 -1.97 2.41 32 -0.07 2.52 2.4% 2.06 [-1.44, 5.66] Liu 2022 -0.18 4.02 30 -0.8 3.97 30 3.8% 0.62 [-1.40, 2.64] Liu 2022 -0.18 4.02 30 -2.45 3.8% 0.71 1.81 1.95 Pei 2016 -3.07 4.81 30	
Chen 2016 5.97 7.23 30 2.41 3.63 30 3.5% 3.56 [0.67, 6.45] Chen 2018 -0.02 2.48 20 0.11 1.56 20 4.0% -0.13 [1.41, 1.15] Guo 2013 -6.04 6.17 30 -1.36 6.38 30 3.5% 4.88 [7.86, -1.50] Li 2009 -1.31 5.45 30 -3.9 5.17 30 3.6% 2.59 [-0.10, 5.28] Li 2020 -1.97 2.41 32 -0.07 2.52 32 4.0% -1.90 [-3.11, -0.69] Liao 2018 4.27 6.97 29 2.21 6.63 29 3.4% 2.06 [-1.44, 5.56] Liu 2022 -1.83 30 -0.52 3.53 30 3.9% 2.45 [0.69, 4.21] Pan 2013 0.31 .59 31 0.24 3.88 30 3.8% 0.07 [-1.81, 1.95] Pei 2016 -3.07 4.81 30 2.86 1.27 [-1.54, 4.08] Wang 2016	
Chen 2018 -0.02 2.48 20 0.11 1.56 20 4.0% -0.13 [-1.41, 1.15] Guo 2013 -6.04 6.17 30 -1.36 6.38 30 3.5% -4.68 [-7.86, -1.50] Li 2009 -1.31 5.45 30 -3.9 5.17 30 3.6% 2.59 [-0.10, 5.28] Li 2020 -1.97 2.41 32 -0.07 2.52 32 4.0% -1.90 [-3.11, -0.69] Liao 2018 4.27 6.97 29 2.21 6.63 29 3.4% 2.06 [-1.44, 5.56] Liu 2022 -0.18 4.02 30 -0.52 3.53 30 3.9% 0.62 [-1.40, 2.64] Pan 2013 0.31 3.59 31 0.24 3.88 30 3.8% 0.07 [-1.81, 1.95] Pel 2016 -3.07 4.81 30 2.28 5.42 30 3.6% 1.27 [-1.54, 4.08] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9%	
Guo 2013 -6.04 6.17 30 -1.36 6.38 30 3.5% -4.68 [-7.86, -1.50] Li 2009 -1.31 5.45 30 -3.9 6.17 30 3.6% 2.56 [-1.00, 5.28] Li 2020 -1.97 2.41 32 -0.07 2.52 2.40% -1.90 [-3.11, -0.69] Liao 2018 4.27 6.97 29 2.21 6.63 29 3.4% 2.06 [-1.44, 5.56] Liu 2022 -0.18 4.02 30 -0.6 3.97 30 3.8% 0.06 [-1.40, 2.64] Liu 2022 -0.18 4.02 30 -0.25 3.53 3.8% 0.06 [-1.40, 2.64] Liu 2022 -0.33 3.43 30 -2.25 3.53 3.8% 0.07 [-1.81, 1.95] Pei 2016 -3.07 4.81 30 2.28 5.42 30 3.6% -5.35 [-7.94, -2.76] Qin 2012 -0.73 4.09 15 -2 3.76 1.30% +13.01 [-4.45, -11.67] Wang 2016 -13.28 4.01 70 -2.27 4.1 70 3.9% </td <td></td>	
Li 2009 -1.31 5.45 30 -3.9 5.17 30 3.6% 2.59[-0.10, 5.28] Li 2020 -1.97 2.41 32 -0.07 2.52 32 4.0% -1.90[-3.11, -0.69] Liao 2018 4.27 6.97 29 2.21 6.63 29 3.4% 2.06 [-1.44, 5.56] Liu 2022 -0.18 4.02 30 -0.8 3.97 30 3.8% 0.62 [-1.40, 2.64] Liu 2022 1.93 3.43 30 -0.52 3.53 30 3.9% 2.45[0.69, 4.21] Pan 2013 0.31 3.59 31 0.24 3.88 30 3.8% 0.07 [-1.81, 1.95] Pei 2016 -3.07 4.81 30 2.28 5.42 30 3.6% 5.35 [-7.94, -2.76] Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% 1.27 [-1.54, 4.08] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% -13.01 [-14.3, 2.53] Wu 2016 -2.2 10.24 20 1.74 10.35 20 2.4% -3.94 [-10.32, 2.44]	
Li 2020 -1.97 2.41 32 -0.07 2.52 32 4.0% -1.90 [-3.11, -0.69] Liao 2018 4.27 6.97 29 2.21 6.63 29 3.4% 2.06 [-1.44, 5.56] Liu 2022 -0.18 4.02 30 -0.62 3.53 30 3.8% 0.62 [-1.40, 2.64] Liu 2022 1.93 3.43 30 -0.52 3.53 30 3.9% 2.45 [0.69, 4.21] Pan 2013 0.31 3.59 31 0.24 3.88 30 3.8% 0.07 [-1.81, 1.95] Pel 2016 -3.07 4.81 30 2.28 5.42 30 3.6% -5.35 [-7.94, -2.76] Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% 1.27 [-1.54, 4.08] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% 1.30 1[-41.35, -11.67] Wang 2023 -1.26 3 30 -2.46 2.21 30 3.9% 1.20 [-0.13, 2.53] Wu 2016 -2.2 10.24 20 1.74 10.35 20 2.4% -3.94 [-1.032, 2.44]	
Liao 2018 4.27 6.97 29 2.21 6.63 29 3.4% 2.06 [-1.44, 5.56] Liu 2022 -0.18 4.02 30 -0.8 3.97 30 3.8% 0.02 [-1.44, 2.54] Liu 2022 -1.93 3.43 30 -0.52 3.53 30 3.8% 0.02 [-1.44, 2.64] Pan 2013 0.31 3.59 31 0.24 3.88 30 3.8% 0.07 [-1.81, 1.95] Pei 2016 -3.07 4.81 30 2.28 5.42 30 3.6% -5.35 [-7.94, -2.76] Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% -5.35 [-7.94, -2.76] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% -13.01 [-14.35, -11.67] Wang 2023 -1.26 3 30 -2.46 2.21 30 3.9% -3.94 [-10.32, 2.44]	
Liu 2022 -0.18 4.02 30 -0.8 3.97 30 3.8% 0.62 [-1.40, 2.64] Liu 2022 1.93 3.43 30 -0.52 3.53 30 3.9% 2.45 [0.69, 4.21] Pan 2013 0.31 3.59 31 0.24 3.88 30 3.9% 2.45 [0.69, 4.21] Pei 2016 -3.07 4.81 30 2.28 5.42 30 3.6% 0.07 [-1.81, 1.95] Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% 1.27 [-1.54, 4.08] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% -13.01 [+4.35, 1-1.67] Wang 2023 -1.26 3 30 -2.4% -2.49 1.20 [-0.13, 2.54] Wu 2016 -2.2 10.24 20 1.74 1.035 20 2.4% -3.94 [-10.32, 2.44]	
Liu 2022 1.93 3.43 30 -0.52 3.53 30 3.9% 2.45 [0.69, 4.21] Pan 2013 0.31 3.59 31 0.24 3.88 30 3.6% 0.07 [-15, 11, 155] Pei 2016 -3.07 4.81 30 2.28 5.42 30 3.6% 1.27 [-1, 54, 4.08] Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% 1.27 [-1, 54, 4.08] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% -13.01 [-14.35, -11.67] Wang 2023 -1.26 3 30 -2.46 2.21 30 3.9% 1.20 [-0.32, 2.53] Wu 2016 -2.21 2.24 20 1.74 10.35 20 2.4% -3.94 [-10.32, 2.44]	
Pan 2013 0.31 3.59 31 0.24 3.88 30 3.8% 0.07 [-1.81, 1.95] Pei 2016 -3.07 4.81 30 2.28 5.42 30 3.6% -5.35 [-7.94, 2.76] Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% -5.35 [-7.94, 2.76] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% -13.01 [-14.35, -11.67] Wang 2023 -1.26 3 30 -2.46 2.21 30 3.9% -3.34 [-10.32, 2.53] Wu 2016 -2.2 10.24 20 1.74 10.55 20 2.4% -3.94 [-10.32, 2.44]	
Pei 2016 -3.07 4.81 30 2.28 5.42 30 3.6% -5.35 [7.94, -2.76] Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% 1.27 [-1.54, 4.08] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% -13.01 [-1.435, -11.67] Wang 2023 -1.26 3 0 -2.4 2.21 30 3.9% -3.94 [-10.32, 2.43]	
Qin 2012 -0.73 4.09 15 -2 3.76 15 3.6% 1.27 [-1.54, 4.08] Wang 2016 -13.28 4.01 70 -0.27 4.1 70 3.9% -13.01 [-14.35, -11.67] Wang 2023 -1.26 3 30 -2.46 2.21 30 3.9% 1.20 [-0.13, 2.53] Wu 2016 -2.2 10.24 20 1.74 10.35 20 2.4% -3.94 [-10.32, 2.44]	
Wang 2023 -1.26 3 30 -2.46 2.21 30 3.9% 1.20 [-0.13, 2.53] Wu 2016 -2.2 10.24 20 1.74 10.35 20 2.4% -3.94 [-10.32, 2.44]	
Wu 2016 -2.2 10.24 20 1.74 10.35 20 2.4% -3.94 [-10.32, 2.44]	
Xiang 2022 -5.56 1.59 34 -3.43 1.65 34 4.0% -2.13 [-2.90, -1.36]	
Xing 2022 -0.25 3.2 29 3.72 3.52 29 3.9% -3.97 [-5.70, -2.24]	
Xiong 2017 -2.58 6.33 38 2.34 6.46 38 3.6% -4.92 [-7.80, -2.04]	
Xu 2012 0.57 3.02 30 2.84 3.67 30 3.9% -2.27 [-3.97, -0.57]	
Xu 2024 -9.58 3.09 30 -5.73 3.58 30 3.9% -3.85 [-5.54, -2.16]	
Xue 2013 0.31 3.59 32 0.24 3.88 32 3.8% 0.07 [-1.76, 1.90]	
Yang 2021 0.22 3.28 33 0.03 2.63 32 3.9% 0.19 [-1.25, 1.63]	
Zhang 2017 -7.77 2.03 30 -1.67 1.92 30 4.0% -6.10 [-7.10, -5.10]	
Zhao 2022 4.77 2.94 34 1.26 4.1 34 3.9% 3.51 [1.81, 5.21]	
Zhao 2023 -2.41 6.65 32 -0.69 5.72 33 3.5% -1.72 [-4.74, 1.30]	
Zhou 2019 0.44 7.57 30 -0.4 8.51 30 3.2% 0.84 [-3.24, 4.92]	
Total (95% CI) 837 836 100.0% -1.56 [-3.09, -0.03]	
Hotorogopoity: $T_{012} = 15.04$; Chi2 = 552.50, df = 26 /B < 0.00001); I2 = 0.5%	
Test for overall effect: Z = 2.00 (P = 0.05) - 20 (P < 0.0001), P = 95 % -10 -5 0 5 10 Favours [control] Favours [contr	ntall
ravours [control] ravours [experiment	indij


Mean Difference Mean Difference Experimental Control Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI IV. Random. 95% CI 4.3.1 Lung cancer Li 2020 0.27 0.17 32 -0.01 0.12 5.4% 0.28 [0.21, 0.35] 32 Wang 2023 Xu 2012 0.57 0.31 -0.07 0.17 30 0.03 0.16 -0.61 0.16 30 5.1% 5.3% 0.54 [0.42, 0.66] 0.54 [0.46, 0.62] 30 30 Zhang 2017 Zhao 2023 Subtotal (95% CI) 4.8% 3.8% 24.4% 0.47 0.33 30 0.23 0.26 30 0.24 [0.09, 0.39] 32 154 33 155 0.19 [-0.07, 0.45] 0.37 [0.22, 0.52] 0.29 0.56 0.1 0.51 Heterogeneity: Tau² = 0.02; Chi² = 32.96, df = 4 (P < 0.00001); l² = Test for overall effect: Z = 4.91 (P < 0.00001) 88% 4.3.2 Gastrointestinal cancers 5.1% 5.1% Guo 2013 0.46 0.27 30 34 -0.01 0.22 0.69 0.24 30 34 0.47 [0.35, 0.59] 0.61 [0.49, 0.73] Xiang 2022 1.3 0.28 29 33 -0.4 0.28 0.03 0.15 29 32 4.9% 5.1% 0.38 [0.24, 0.52] 0.52 [0.40, 0.64] Xing 2022 -0.02 0.26 Yang 2021 0.55 0.32 Zhang 2011 Subtotal (95% CI) 0.38 0.31 35 161 0.08 0.43 35 160 4.6% 24.7% 0.30 [0.12, 0.48] 0.47 [0.37, 0.56] Heterogeneity: Tau² = 0.01; Chi² = 10.69, df = 4 (P = 0.03); l² = 63% Test for overall effect: Z = 9.27 (P < 0.00001) 4.3.3 Breast cancer Chen 2018 Subtotal (95% CI) 20 -0.09 0.11 20 5.4% 5.4% 0.04 [-0.04, 0.12] 0.04 [-0.04, 0.12] -0.05 0.15 20 20 Heterogeneity: Not applicable Test for overall effect: Z = 0.96 (P = 0.34) 4.3.4 Other cancers 0.22 [0.03, 0.41] Chen 2004 -0.01 0.29 28 -0.23 0.42 28 4.5% Jiang 2020 -0.15 0.14 0.3 0.4 44 -0.34 0.15 0.06 0.4 44 29 5.5% 0.19 [0.13, 0.25] 29 4.3% 0.24 [0.03, 0.45] Liao 2018 Liu 2022 -0.01 0.15 30 30 15 20 41 38 -0.06 0.16 30 5.4% 0.05 [-0.03, 0.13] 30 15 Liu 2022 0.1 0.15 0.1 0.13 0.1 0.21 5.4% 0.00 [-0.07. 0.07] 0.43 0.01 [-0.23, 0.25] 0.51 [-0.17, 1.19] Qin 2012 0.11 4.0% Wu 2016 -0.11 1.23 1.3% 0.4 20 0.48 0.25 0.2 0.71 0.25 0.17 -0.18 0.68 41 38 5.3% 3.3% 0.23 [0.14, 0.32] 0.38 [0.07, 0.69] Wu 2021 Xiong 2017 Xu 2024 0.72 0.3 30 30 0.27 0.32 30 30 4.8% 0.45 [0.29, 0.61] Zhou 2019 0.13 1.08 0.17 1.13 1.7% -0.04 [-0.60, 0.52] Subtotal (95% CI) 335 335 45.5% 0.18 [0.09, 0.27] Heterogeneity: Tau² = 0.01; Chi² = 47.71, df = 10 (P < 0.00001); l² = 79% Test for overall effect: Z = 3.90 (P < 0.0001) Total (95% CI) 670 670 100.0% 0.29 [0.20, 0.38] Heterogeneity: Tau² = 0.04; Chi² = 249.45, df = 21 (P < 0.00001); l² = 92% -0.5 ò 0.5 -1 Test for overall effect: Z = 6.43 (P < 0.00001) Test for subaroup differences: Chi² = 47.42. df = 3 (P < 0.00001). l² = 93.7% Favours [control] Favours [experimental] FIGURE 6 Forest plot for the $CD4^+/CD8^+$ level of malignant tumors patients (n=21).

Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% Cl IV. Random, 95% Cl S3.1 Lung cancer Mao 2022 3.15 5.81 17 -3.18 5.83 16 6.2% 6.33 [2.51, 10.15] Pel 2016 3.4 2.75 30 -6.41 8.81 30 6.7% 9.81 [6.13, 11.49] Wang 2016 2.002 8.01 1.8 34 2.78 1.84 44 6.8% 5.23 [4.26, 6.10] Subtotal (9% Cl) 151 150 2.65.% 1.170 [1.36, 22.05] 1.107 [1.37, 22.05] Fest for overall effect: Z = 2.22 (P = 0.03) 5.32 6.8% 5.23 [1.06, 53, 33] 1.07 2.57 3.59 3.119 2.81 3.22 6.8% 2.02 [0.65, 3.39] 3.22 [0.65, 3.93] 3.22 [0.65, 3.561] 1.72 3.43 5.0 2.62 (P = 0.04) 5.62 1.6 2.22 (D .63, 3.561] 1.65 1.65 1.66 2.02 (D .65, 3.39] 3.22 [0.63, 3.61] 1.65 1.66 1.66 (S - 0.006); P = 0.02; P = 0.02; P = 0.02; P = 0.03; P		Expe	erimen	tal	С	ontro			Mean Difference	Mean Difference
Nae 2022 3.15 5.81 17 -3.18 5.83 16 6.2% 6.33 [251, 10.15] Pei 2016 3.4 2.75 30 -6.41 3.81 30 6.7% 9.81 [8.13, 11.49] Wang 2016 2.6.02 5 70 0.72 3.77 70 6.7% 25.30 [23.83, 26.77] Zhao 2022 8.01 1.8 34 2.78 1.84 34 6.8% 5.23 [4.36, 6.10] Subtotal (9% C1) 151 150 26.5% 11.70 [1.36, 22.05] Heterogeneity: Tau" = 110.12; Chi ^p = 537.93, df = 3 (P < 0.0001); P = 99% Test for overall effect: Z = 2.22 (P = 0.03) 5.3.2 Gastrointestinal cancers Pan 2013 2.57 3.59 31 1.07 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.61 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% C1) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau" = 5.29; Chi ^p = 27.77, df = 3 (P < 0.00001); P = 89% Test for overall effect: Z = 2.64 (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.66 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% C1) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau" = 0.00; Chi ^p = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2016 0.86 5.62 30 1.22 4.06 38 -6.7% 2.69 [0.87, 4.51] Xiung 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Xiung 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Xiung 2017 0.82 4.06 1.96 2.14 40 6.8% Subtotal (95% C1) 151 151 3.3.2% Xiong 2017 0.82 4.06 1.96 2.14 40 6.8% Subtotal (95% C1) 10 151 151 3.3.2% Xiong 2017 0.82 4.06 1.96 2.14 40 6.8% Subtotal (95% C1) 10 151 151 3.3.2% Xiong 2017 0.82 4.06 1.96 2.14 40 6.8% Subtotal (95% C1) 0 0 Not estimable Heterogeneity: Tau" = 1.1.19, df = 4 (P = 0.02); P = 64% Test for overall effect: X -2.9 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% C1) 0 0 Not estimable Heterogeneity: Tau" = 3.8.76; Chi ^p = 96.79, df = 14 (P < 0.00001); P = 99% Test for overall effect: X -2.9 (P = 0.004) Foreuers forcoreal foreticx - Z = 2.9 (P = 0.004) Foreuers forenti	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% Cl
Pei 2016 3.4 2.75 30 -6.41 3.81 30 6.7% 9.81 [8.13, 11.49] Wang 2016 26.02 5 70 0.72 3.77 70 6.7% 2.5.00 [23.83, 26.77] Zhao 2022 8.01 1.8 34 2.78 1.84 34 6.8% 5.23 [43.86, 10] Subtotal (95% CI) 151 150 2.65% 11.70 [1.36, 22.05] Heterogeneity: Tau ² = 10.12; Ch ² = 537.93, df = 3 (P < 0.00001); P = 99% Test for overall effect: $Z = 2.22$ ($P = 0.03$) 5.3.2 Gastrointestinal cancers Pan 2013 2.57 3.59 31 1.07 3.57 30 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2021 7.81 3.16 33 1.19 2.81 32 6.6% 0.20 [6.5, 3.99] Subtotal (95% CI) 131 122 26.9% 3.22 [0.63, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 2.777, df = 3 (P < 0.00001); P = 89% Test for overall effect: $Z = 2.64$ ($P = 0.008$) 5.3.3 Breast cancer Chen 2016 0.66 5.62 30 1.72 4.45 30 6.6% -0.26 [-3.43, 1.71] Chen 2016 1.7 2.03 20 1.43 1.46 0.68% -0.27 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 ($P = 0.68$); P = 0% Test for overall effect: $Z = 0.70$ ($P = 0.48$); $P = 0.96$ Test for overall effect: $Z = 0.70$ ($P = 0.48$); $P = 0.97$ Test for overall effect: $Z = 0.70$ ($P = 0.48$); $P = 0.92$ Test for overall effect: $Z = 2.64$ ($P = 0.02$); $P = 64\%$ S.3.4 Other cancers Chen 2004 0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% Char 2014 1.05; 2.26] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.86 2.14 40 6.8% Zas [1.51, 5.26] Xiong 2017 0.82 2.406 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.86 2.14 40 6.8% Test for overall effect: $Z = 4.29$ ($P < 0.0001$) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 4 ($P = 0.0007$); $P = 99\%$ Test for overall effect: $Z = 4.29$ ($P < 0.0001$) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 ($P < 0.00007$); $P = 99\%$ Test for overall effect: $Z = 2.92$ ($P = 0.0004$) For user	5.3.1 Lung cancer									
Wang 2016 26.02 5 70 0.72 3.77 70 6.7% 25.30 [23.3, 26.77] Zhao 2022 8.01 1.8 34 2.78 1.84 34 6.8% 5.23 [4.36, 6.10] Subtotal [95% CI) 151 150 26.5% 11.70 [1.36, 22.05] Heterogeneity: Tau ² = 110.12; Ch ² = 537.93, df = 3 (P < 0.00001); P = 99% Test for overall effect: Z = 2.22 (P = 0.03) 5.3.2 Gastrointestinal cancers Pan 2013 2.75 3.59 31 1.07 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 27.77, df = 3 (P < 0.00001); P = 89% Test for overall effect: Z = 2.64 (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.63] Subtotal (95% CI) 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] L12009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Total (95% CI) 151 -1 51 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.13; Ch ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Ch ² = 96.79, df = 14 (P < 0.0001); P = 99% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 4.43 440 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Ch ² = 96.79, df = 14 (P < 0.00001); P = 99% Test for overall effect: Z = 2.92 (P = 0.004) Exource forcementention Subtotal (95% CI) 4.83 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.00001); P = 99% Test for overall effect: Z = 2.92 (P = 0.004)	Mao 2022	3.15	5.81	17	-3.18	5.38	16	6.2%	6.33 [2.51, 10.15]	
The 2022 8.01 18 34 2.78 1.84 34 6.8% 5.2[4.36, 6.10] Subtotal (95% CI) 151 150 26.5% 11.70 [1.36, 22.05] Heterogeneity: Tau ² = 110.12; Ch ² = 537.39, df = 3 (P < 0.00001); P = 99% Test for overall effect: $Z = 2.22$ (P = 0.03) 5.3.2 Gastrointestinal cancers Pan 2013 2.57 3.59 31 1.07 3.57 30 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Subtotal (95% CI) 131 129 2.85 9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 2.05; Ch ² = 2.77, 7d f = 3 (P < 0.00001); P = 89% Test for overall effect: $Z = 2.64$ (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 0.7, 203 20 1.43 1.46 20 6.8% 4.027 [1.37, 0.83] Subtotal (95% CI) 50 150 13.4% -0.36 [-1.37, 0.85] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 2.26 5.27 30 6.6% 1.01 [1.13, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] S.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 2.26 5.27 30 6.6% 1.01 [1.13, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.59 [1.56, 3.44] Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Tau ² = 3.8.76; Ch ² = 968.79, df = 14 (P < 0.0001); P = 98% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 Not estimable Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.0001); P = 98% Test for overall effect: X = 2.9 (P = 0.004) For any regimental effect: X = 2.9 (P = 0.004)	Pei 2016	3.4	2.75	30	-6.41	3.81	30	6.7%	9.81 [8.13, 11.49]	-
Subtotal (95% CI) 151 150 26.5% 11.70 [r.36, 22.05] Heterogeneity: Tau ² = 110.12; Ch ²² = 537.93, df = 3 ($P < 0.00001$); $P = 99\%$ Test for overall effect: $Z = 2.22 (P = 0.03)$ 5.3.2 Gastrointestinal cancers Pan 2013 2.57 3.59 31 107 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [517, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 129 28.9% Test for overall effect: $Z = 2.54 (P = 0.008)$ 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 ($P = 0.68$); $P = 0\%$ Test for overall effect: $Z = 0.70 (P = 0.48)$ 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Viong 2017 0.82 4.06 38 1.87 40.2 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 351 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Ch ² = 11.19, df = 4 ($P = 0.02$); $P = 64\%$ Test for overall effect: $Z = 4.29 (P < 0.0001)$ 5.3.5 [Chineal intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 ($P < 0.0001$); $P = 99\%$ Test for overall effect: $Z = 4.29 (P < 0.0001)$ 5.3.5 [Chineal intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 ($P < 0.00001$); $P = 99\%$ Test for overall effect: $Z = 2.29 (P = 0.004)$	Wang 2016	26.02	5	70	0.72	3.77	70	6.7%		
Heterogeneity: Tau ² = 110.12: Ch ² = 537.93, df = 3 (P < 0.0001); P = 99% Test for overall effect: $Z = 2.22$ (P = 0.03) 5.3.2 Gastrointestinal cancers Pan 2013 2.67 3.59 31 1.07 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 - 0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 122 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 27.77, df = 3 (P < 0.00001); P = 89% Test for overall effect: Z = 2.64 (P = 0.0008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.85] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 31.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.020); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.6 Clinical intervention Subtotal (95% CI) 0 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.0001); P = 99% Test for overall effect: Z = 4.29 (P = 0.004)	Zhao 2022	8.01	1.8	34	2.78	1.84	34	6.8%	5.23 [4.36, 6.10]	-
Test for overall effect: $Z = 2.22$ (P = 0.03) 5.3.2 Gastrointestinal cancers Pan 2013 2.57 3.59 31 1.07 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 1 31 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 27.77, df = 3 (P < 0.00001); P = 89% Test for overall effect: $Z = 2.64$ (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Chi ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2014 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Oin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: $Z = 4.29$ (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Test for overall effect: $Z = 4.29$ (P < 0.0001) 5.3.6 Clinical intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Test for overall effect: $Z = 4.29$ (P < 0.0001); P = 99% Test for overall effect: $Z = 4.29$ (P < 0.0001) 2.00 -10 0 10 20 2.00 -10 0 0 10 20 2.00 -10 0 0 10 20 2.00 -10 0 0 10 20 3.01 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Subtotal (95% CI)			151			150	26.5%	11.70 [1.36, 22.05]	
Test for overall effect: $Z = 2.22$ (P = 0.03) 5.3.2 Gastrointestinal cancers Pan 2013 2.57 3.59 31 1.07 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 1 31 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 27.77, df = 3 (P < 0.00001); P = 89% Test for overall effect: $Z = 2.64$ (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Chi ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2014 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Oin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: $Z = 4.29$ (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Test for overall effect: $Z = 4.29$ (P < 0.0001) 5.3.6 Clinical intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Test for overall effect: $Z = 4.29$ (P < 0.0001); P = 99% Test for overall effect: $Z = 4.29$ (P < 0.0001) 2.00 -10 0 10 20 2.00 -10 0 0 10 20 2.00 -10 0 0 10 20 2.00 -10 0 0 10 20 3.01 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Heterogeneity: Tau ² =	110.12;	Chi ² =	537.93	, df = 3	(P < 0	.00001	; l ² = 99%		
Pan 2013 2.57 3.59 31 1.07 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.49 32 0.68% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 2.77.7 (f = 3 (P < 0.00001); P = 89% Test for overall effect: $Z = 2.64$ (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.66 5.62 30 1.72 4.45 30 6.6% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Chi ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.170 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 4.0 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.002); P = 99% Test for overall effect: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.002); P = 99% Test for overall effect: Not applicable Test for overall effect: Not applicable Test for overall effect: $Z = 2.92 (P = 0.004)$	Test for overall effect:	Z = 2.22	! (P = 0	.03)						
Pan 2013 2.57 3.59 31 1.07 3.57 30 6.7% 1.50 [-0.30, 3.30] Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.49 32 0.68% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 2.77.7 (f = 3 (P < 0.00001); P = 89% Test for overall effect: $Z = 2.64$ (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.66 5.62 30 1.72 4.45 30 6.6% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Chi ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.170 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 4.0 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.002); P = 99% Test for overall effect: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.002); P = 99% Test for overall effect: Not applicable Test for overall effect: Not applicable Test for overall effect: $Z = 2.92 (P = 0.004)$	5.3.2 Gastrointestina	al cancer	s							
Xue 2013 3.19 3.49 32 0.52 3.56 32 6.7% 2.67 [0.94, 4.40] Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 27.77, df = 3 (P < 0.00001); l ² = 89% Test for overall effect: Z = 2.64 (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -22.6 5.27 30 6.6% 1.01 [-1.31, 3.33] Gin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Ch ² = 1.11.9, df = 4 (P = 0.02); I ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.000); I ² = 99% Test for overall effect: X = 2.92 (P = 0.000) Feast for overall effect: X = 2.92 (P = 0.004) Feast for overall effect: X = 2.92 (P = 0.004) Feast for overall effect: X = 2.92 (P = 0.004)				31	1 07	3 57	30	67%	1 50 [-0 30 3 30]	
Yang 2021 7.81 3.16 33 1.19 2.81 32 6.8% 6.62 [5.17, 8.07] Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 27.77, df = 3 (P < 0.00001); l ² = 89% Test for overall effect: Z = 2.64 (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Ch ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.0001); l ² = 99% Total (95% CI) 0 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Not applicable Total (95% CI) 0 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Not applicable Total (95% CI) 0 10 0 Total (95% CI) 0 0 0 Favours [controll Favours [contr										-
Zhang 2011 1.72 3.34 35 -0.3 2.42 35 6.8% 2.02 [0.65, 3.39] Subtotal (95% CI) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Ch ² = 2.77, df = 3 (P < 0.0001); l ² = 89% Test for overall effect: Z = 2.64 (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); l ² = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Ch ² = 11.19, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Total (95% CI) 0 10 20 Eavours [corporal] Encyclic Enc										-
Subtotal (95% Cl) 131 129 26.9% 3.22 [0.83, 5.61] Heterogeneity: Tau ² = 5.29; Chi ² = 27.77, df = 3 (P < 0.00001); I ² = 89% Test for overall effect: Z = 2.64 (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% Cl) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Chi ² = 0.17, df = 1 (P = 0.68); I ² = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.59 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% Cl) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 1.19, df = 4 (P = 0.02); I ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); I ² = 99% Total (95% Cl) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneily: Tau ² = 38.76; Chi ² = 96.79, df = 14 (P < 0.00001); I ² = 99% Total (95% Cl) 0 10 20 Eavours [corported] Environ Eavours [serperimental Heterogeneily: Tau ² = 38.76; Chi ² = 96.79, df = 14 (P < 0.00001); I ² = 99% Total (95% Cl) 0 10 20 Eavours [serperimental effect: Set = 2.92 (P = 0.004)										-
Heterogeneity: $Tau^2 = 5.29$; $Chi^2 = 27.77$, $df = 3$ (P < 0.00001); I ² = 89% Test for overall effect: $Z = 2.64$ (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% Cl) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.17$, $df = 1$ (P = 0.68); I ² = 0% Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% Cl) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); I ² = 64% Test for overall effect: $Z = 4.29$ (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% Cl) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% Cl) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% Cl) Chi 2 = 2.92 (P = 0.004)		1.72	0.04		-0.5	2.42				•
Test for overall effect: $Z = 2.64$ (P = 0.008) 5.3.3 Breast cancer Chen 2016 0.86 5.62 30 1.72 4.45 30 6.6% -0.86 [-3.43, 1.71] Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.57 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Ch ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: $Z = 4.29$ (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Tau ² = 3.8.76; Ch ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 3.8.76; Ch ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% CL) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 3.2.72; Ch ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% CL) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 3.2.72; Ch ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% CL) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 3.2.72; Ch ² = 968.79, df = 14 (P < 0.0001); I ² = 99% Total (95% CL) 5.3.5 Ch ² = 2.92; CP = 0.004)		5 29 CH	$ni^2 = 27$		= 3 (P -	< 0.00			0.22 [0.000] 0.01]	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					- 0 (i	- 0.00	001), 1	0070		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	E 2 2 Dreast server									
Chen 2018 -1.7 2.03 20 -1.43 1.46 20 6.8% -0.27 [-1.37, 0.83] Subtotal (95% CI) 50 50 13.4% -0.36 [-1.37, 0.65] Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); l ² = 0% Test for overall effect: Z = 0.70 (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.59 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 1.19, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Tau ² = 3.8.76; Chi ² = 968.79, df = 14 (P < 0.0001); l ² = 99% Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 3.8.76; Chi ² = 968.79, df = 14 (P < 0.0001); l ² = 99% Total (95% CL) 2.92 (P = 0.004)					4 70			0.001		
Subtotal (95% CI) 50 50 13.4% -0.36 $[-1.37, 0.65]$ Heterogeneity: Tau ² = 0.00; Ch ² = 0.17, df = 1 (P = 0.68); P = 0% 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Ch ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.0001); P = 99% Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.0001); P = 99% Total (95% CI) 6 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Cau ² = 2.92 (P = 0.004)										1
Heterogeneity: Tau ² = 0.00; Chi ² = 0.17, df = 1 (P = 0.68); P = 0% Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% Cl) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); P = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); P = 99% Total (95% Cl) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneil effect: Z = 2.92 (P = 0.004)		-1.7	2.03		-1.43	1.46				1
Test for overall effect: $Z = 0.70$ (P = 0.48) 5.3.4 Other cancers Chen 2004 -0.9 1.93 28 -5.6 2.9 28 6.8% 4.70 [3.41, 5.99] Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneil effect: Z = 2.92 (P = 0.004) Favours [corported] Eavours [serperimential Eavours [serperiment	. ,	0.00.01	.:2 - 0		1 (D -	0.001.		13.4%	-0.30 [-1.37, 0.05]	1
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					1 (P =	0.68);	1~ = 0%			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$										
Li 2009 -1.25 3.76 30 -2.26 5.27 30 6.6% 1.01 [-1.31, 3.33] Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.36, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% Cl) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Ch ² = 1.11, 9, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneily: Tau ² = 38.76; Ch ² = 968.79, df = 14 (P < 0.0001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004) Favours [correct] Eavours [experimental]			4 00			~ ~		0.001	1 70 10 11 5 001	-
Qin 2012 0.7 5.03 15 -1 4.88 15 6.3% 1.70 [-1.85, 5.25] Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 [0.87, 4.51] Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 [1.56, 3.44] Subtotal (95% CI) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity: Not applicable Test for overall effect: Z = 4.29 (P < 0.0001); l ² = 99% Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004) -20 - 10 0 10 20 Eavours [controll Eavours [experimental feater is the program of the program of the program is the program of the program of the program is the program of the program of the program is the program of the progra										
Xiong 2017 0.82 4.06 38 -1.87 4.02 38 6.7% 2.69 $[0.87, 4.51]$ Zhu 2023 4.46 2.16 40 1.96 2.14 40 6.8% 2.50 $[1.56, 3.44]$ Subtotal (95% Cl) 151 151 33.2% 2.78 $[1.51, 4.06]$ Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 483 480 100.0% Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004) -20 -10 0 10 20 Eavours [control = Eavours [control =										
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$										-
Subtotal (95% Cl) 151 151 33.2% 2.78 [1.51, 4.06] Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 483 480 100.0% Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004) -20 -10 0 10 20 Eavours [experimental Equation Sequence of the sequence										12 I
Heterogeneity: Tau ² = 1.23; Chi ² = 11.19, df = 4 (P = 0.02); l ² = 64% Test for overall effect: Z = 4.29 (P < 0.0001) 5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 483 480 100.0% Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004) Favours [control] Eavours [experimental		4.46	2.16		1.96	2.14				
Test for overall effect: Z = 4.29 (P < 0.0001)						0.00			2.78 [1.51, 4.06]	•
5.3.5 Clinical intervention Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 483 480 100.0% Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004) Favours [control] Eavours [experiments]					= 4 (P =	= 0.02); $1^2 = 6^2$	%		
Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% 4.75 [1.56, 7.94] -20 -10 0 10 20 Test for overall effect: Z = 2.92 (P = 0.004) Exercise Control Integration -20 -10 0 10 20	rest for overall effect:	2 = 4.29	(P < 0	.0001)						
Heterogeneity: Not applicable Test for overall effect: Not applicable Total (95% Cl) 483 480 100.0% Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004) -20 -10 0 10 20 Favours [control] Favours [control]	5.3.5 Clinical interve	ntion								
Test for overall effect: Not applicable Total (95% Cl) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% 4.75 [1.56, 7.94] -20 -10 0 10 20 Test for overall effect: Z = 2.92 (P = 0.004) Eavours [construint] -20 -10 0 10 20	Subtotal (95% CI)			0			0		Not estimable	
Test for overall effect: Not applicable Total (95% CI) 483 480 100.0% 4.75 [1.56, 7.94] Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% 4.75 [1.56, 7.94] -20 -10 0 10 20 Test for overall effect: Z = 2.92 (P = 0.004) Eavours [experimental Equation of the second of the seco	Heterogeneity: Not ap	plicable								
Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004)			licable							
Heterogeneity: Tau ² = 38.76; Chi ² = 968.79, df = 14 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.92 (P = 0.004)	Total (95% CI)			483			480	100.0%	4.75 [1.56, 7.94]	+
Test for overall effect: $Z = 2.92$ (P = 0.004) Favours [control] Favours [control		38 76 0	$chi^2 = 0$		df = 14	(P < 0				
					a. 14			, 00 /0	,	
					df = 3/	P < 0.	0001) #	= 86.3%		Favours [control] Favours [experimental
		0.01000.		- 1.00.	a 01			00.070		

Forest plot for the NK level of malignant tumors patients (n=15).

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
5.4.1 Combination cl									
Chen 2004		1.93	28	-5.6	2.9	28	6.8%	4.70 [3.41, 5.99]	-
Chen 2016		5.62	30		4.45	30	6.6%	-0.86 [-3.43, 1.71]	-
Li 2009	-1.25			-2.26		30	6.6%	1.01 [-1.31, 3.33]	
Mao 2022		5.81		-3.18		16	6.2%	6.33 [2.51, 10.15]	
Pei 2016		2.75		-6.41		30	6.7%	9.81 [8.13, 11.49]	-
Wang 2016	26.02	5	70		3.77	70	6.7%	25.30 [23.83, 26.77]	-
Xiong 2017		4.06		-1.87		38	6.7%	2.69 [0.87, 4.51]	-
Zhao 2022	8.01	1.8	34		1.84	34	6.8%	5.23 [4.36, 6.10]	+
Subtotal (95% CI)			277			276	53.2%	6.80 [1.03, 12.58]	
Heterogeneity: Tau ² =	68.24: C	$chi^2 = 7$	15.49.	df = 7 (P < 0.	00001):	$ ^2 = 99\%$	-	
Test for overall effect:									
5.4.2 Combined surg	ery								
Chen 2018	-1.7	2.03	20	-1.43	1.46	20	6.8%	-0.27 [-1.37, 0.83]	+
Subtotal (95% CI)			20			20	6.8%	-0.27 [-1.37, 0.83]	+
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 0.48	(P = 0	.63)						
5.4.3 Combined othe	r therap	ies							
Pan 2013	2.57	3.59	31	1.07	3.57	30	6.7%	1.50 [-0.30, 3.30]	-
Qin 2012	0.7	5.03	15	-1	4.88	15	6.3%	1.70 [-1.85, 5.25]	
Xue 2013	3.19	3.49	32	0.52	3.56	32	6.7%	2.67 [0.94, 4.40]	-
Yang 2021	7.81	3.16	33	1.19	2.81	32	6.8%	6.62 [5.17, 8.07]	+
Zhang 2011	1.72	3.34	35	-0.3	2.42	35	6.8%	2.02 [0.65, 3.39]	-
Zhu 2023	4.46	2.16	40	1.96	2.14	40	6.8%	2.50 [1.56, 3.44]	1
Subtotal (95% CI)			186			184	40.1%	2.93 [1.36, 4.51]	•
Heterogeneity: Tau ² =	3.04; Ch	ni² = 30	.24, df	= 5 (P	< 0.00	01); l ² =	83%		
Test for overall effect:	Z = 3.65	(P = 0	.0003)						
Total (95% CI)			483			480	100.0%	4.75 [1.56, 7.94]	◆
Heterogeneity: Tau ² =				df = 14	(P < 0	.00001); l ² = 99%		-20 -10 0 10 20
Test for overall effect:	Z = 2.92	(P = 0	.004)						Favours [control] Favours [experimental]
Test for subaroup diffe	erences:	Chi ² =	14.80.	df = 2 (P = 0.	0006). I ^s	2 = 86.5%		ravous (control) ravous (expelimental)

Forest plot for the NK level of malignant tumors patients (n=15).



promote the growth of tumor cells to a certain extent, increase the risk of metastasis and recurrence, and is not conducive to the prognosis (60), and most patients exhibit a decrease in CD3⁺ and CD4⁺, leading to an imbalance of CD4⁺/CD8⁺ and a predominance of cell-mediated immune negative effects (61). The study by Muhammad Ramzan et al. showed that high infiltration of CD8⁺ cells in tumor tissue suggests a high recurrence rate and poor prognosis in HCC patients (62). Similarly, in colorectal cancer patients, studies have shown that high CD8⁺ T lymphocyte content may be associated with adverse clinical outcomes, and a decrease in CD4⁺ T lymphocyte content and a decrease in the CD4⁺/CD8⁺ ratio indicate that CRC is in a progressive state and undergoing accelerated proliferation (63). In lung cancer and melanoma patients, CD8⁺ T cell levels are low before treatment and ultimately derive a durable benefit from immunotherapy (64, 65).


The possible reasons for CD8⁺ cell elevation being associated with poor prognosis in patients are as follows: in the context of long-term suppressive tumor microenvironment, tumor-specific CD8⁺ T lymphocytes are prone to enter the "T lymphocyte exhaustion of function" stage (66–68), characterized by increased expression of immune inhibitory receptors such as lymphocyte activation gene 3 (LAG-3), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and T cell immunoglobulin 3 (TIM-3) on the surface of lymphocytes, impaired production of cytokines such as IL-2, TNF α , and IFN γ , and impaired tumor killing ability (69,

SE(MD) 000 °00 0000 0 00 0 0 00 0 0 0 С 0 MD -10 10 FIGURE 10 Funnel plot showing publication bias; CD3⁺

70). Relevant studies show that the increase of CD8 ⁺T cells may be related to the mechanism of tumor immune escape (71). This also suggests that in the future further researches on the effect of acupuncture on CD8⁺ cell function are needed.CD4⁺ cells and CD8⁺ cells are mutually inducing and restraining, forming a network of cells that is important for regulating immune responses and maintaining immune homeosta (72). When the CD8⁺ cells increases, the ratio of the CD4⁺ and CD8⁺ cells changes, it can cause the immune function of the body to decrease, thereby weakening the anti-tumor ability of the body (73). Meanwhile, CD8⁺ T cells have cytotoxic effects on antigen presenting cells, they can also inhibit the anti-tumor effect of CD4⁺ cells by producing inhibitory cytokines (74).

Furthermore, a compelling body of clinical evidence reveals that these traditional therapies can significantly improve the humoral immune levels and cytokine profiles of cancer patients. For instance, research has demonstrated that acupuncture and moxibustion can elevate key humoral immune markers such as IgM, IgG, C3, and C4 (48) and reduce TNF- α , TGF- β 1 levels, increase IL-2 levels in tumor patients (24, 33, 41, 42), suggesting a potential mechanism for bolstering the body's immune defenses against cancer.

Subgroup analysis showed that different acupuncture and moxibustion methods were one of the main sources leading to heterogeneity of $CD3^+$ and $CD4^+$. The heterogeneity of $CD4^+/CD8^+$



13

and NK cells is caused by different types of cancer, and the heterogeneity of NK cells is also caused by different stages of treatment.

In the field of clinical research, the selected acupoints and the determined treatment duration exhibit a relatively diverse range of characteristics. This study focuses on conducting subgroup analyses based on two key factors: whether the Zusanli acupoint is selected and whether the treatment duration exceeds 30 days. The analysis results indicate that these two factors are not the root causes of the heterogeneity in this study. However, the clinical issue of how to select the optimal acupoints and determine the optimal treatment duration to effectively enhance the immune function of cancer patients remains at a stage that requires in-depth research and exploration. More high-quality research results are needed to provide strong evidence and references.

Limitations

The meta-analysis has several limitations. Due to limited resources, this study only retrieved eight databases of published studies, which were all in Chinese or English. All included patients were from China. The single - source samples inevitably caused racial and genetic bias. They can't adequately represent the diversity and complexity in disease features and genetic background across different races. This may limit the generalizability of the research findings. In addition, the majority of the included studies had small sample sizes, which may limit the persuasiveness of the results to some extent. Due to the uniqueness of acupuncture and moxibustion, all trials included in the study were not blinded to the acupuncturis. None of the 33 studies followed patients for a long time, so we cannot know the long-term effects of acupuncture and moxibustion on cancer patients. In the publication bias section, there was publication bias in CD3⁺ and CD4⁺ studies. This bias may be related to negative results not being published.

Implications for future research and clinical practice

In clinical practice, acupuncture and moxibustion can be used as an auxiliary therapeutic measure for patients who can accept it. Based on the above limitations, more large-sample, multi-center and more diverse participant recruitment clinical trials are needed in the future. By including individuals from various racial and ethnic backgrounds, researchers can obtain a broader and more representative dataset. In the study design, strict prospective design methods should be used to ensure the quality of outcomes, especially the blind setting and long-term follow-up of outcome indicators. Only one of the studies included partial patients who combined immunotherapy, and the clinical efficacy of acupuncture therapy to combine immunotherapy needs to be further confirmed by more research. In addition, the optimal acupuncture intervention duration and frequency for enhancing immune function need to be further explored in future studies.

Conclusion

In summary, in this systematic review and meta-analysis of 33 trials, including 1,378 patients with malignant tumors, acupuncture and moxibustion was found to have statistically significant and clinically meaningful effects on improving immune function compared to no acupuncture and moxibustion.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Author contributions

YW: Writing – original draft, Data curation, Writing – review & editing. BS: Data curation, Writing – original draft, Writing – review & editing. YZ: Writing – review & editing. LF: Writing – review & editing. YX: Writing – review & editing. YF: Writing – review & editing. RW: Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by High Level Chinese Medical Hospital Promotion Project - Traditional Chinese Medicine Clinical Evidence-based Research Special Project - Clinical Efficacy Evaluation and Mechanism Research of Potential Advantage Diseases of Acupuncture - Clinical Efficacy Evaluation of Enhancing Immune Response of Cervical Cancer Patients by Acupuncture (HLCMPP 2023089 - 08).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations,

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* (2021) 71(3):209–49. doi: 10.3322/caac.21660

2. Parkin J, Cohen B. An overview of the immune system. Lancet. (2001) 357 (9270):1777-89. doi: 10.1016/S0140-6736(00)04904-7

3. Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res. (2020) 2020:5825401. doi: 10.1155/2020/5825401

4. Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. (2023) 14:1212476. doi: 10.3389/fimmu.2023.1212476

5. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. (2019) 18(3):175–96. doi: 10.1038/s41573-018-0006-z

 Szeto GL, Finley SD. Integrative approaches to cancer immunotherapy. Trends Cancer. (2019) 5(7):400–10. doi: 10.1016/j.trecan.2019.05.010

7. Simmons K, Kee BK, Raghav KPS, Johnson B, Kopetz S, Willis J, et al. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. *J Clin Oncol.* (2022) 40:3585–5. doi: 10.1200/ JCO.2022.40.16_suppl.3585

8. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. (2020) 70(2):86–104. doi: 10.3322/caac.21596

9. Liu F, Wang Y, Lyu K, Du X, Zhou M, Shi J, et al. Acupuncture and its ability to restore and maintain immune homeostasis. *QJM*. (2024) 117(3):167–76. doi: 10.1093/ gjmed/hcad134

10. Wang Y, Liu F, Du X, Shi J, Yu R, Li S, et al. Combination of anti-PD-1 and electroacupuncture induces a potent antitumor immune response in microsatellite-stable colorectal cancer. *Cancer Immunol Res.* (2024) 12(1):26–35. doi: 10.1158/2326-6066.CIR-23-0309

11. Hu D, Shen W, Gong C, Fang C, Yao C, Zhu X, et al. Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer. *J Cell Mol Med.* (2021) 25(6):2900–8. doi: 10.1111/jcmm.16320

12. Li L, Shi Y, Luo M, Zhao CL. Effects of moxibustion on Treg cells in sarcoma microenvironment. J Integr Med. (2021) 19(3):251–7. doi: 10.1016/j.joim.2021.02.001

13. Stone JA, Johnstone PA. Mechanisms of action for acupuncture in the oncology setting. *Curr Treat Options Oncol.* (2010) 11(3-4):118-27. doi: 10.1007/s11864-010-0128-y

14. Saraswati W, Dahlan EG, Saputra K, Sutrisno TC. Effect of electroacupuncture on natural-killer cells and tumor size in patients with cervical squamous-cell carcinoma: A randomized controlled trial. *Med Acupunct.* (2019) 31(1):29–36. doi: 10.1089/acu.2018.1316

15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* (2015) 4(1):1. doi: 10.1186/2046-4053-4-1

16. Zhang L, Han K. How to analyze change from baseline: Absolute or percentage change. D-level Essay in Statistics. Dalarna, Sweden: Dalarna University (2009).

17. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Available online at: https://training.cochrane.org/handbook/current/chapter-06.

18. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928

19. Chuang C, Zuojun Z, Hanzhong L, Tan Z, Lu Y, Huang Z, et al. Clinical observation on the detoxification effect of electroacupuncture at zusanli (ST 36) in chemotherapy. *New Chin Med.* (2004) 03:46–7. doi: 10.13457/j.cnki.jncm.2004.03.024

20. Jun C, Naiqing F, Lei W, Wu X, Xiao H, Sun C, et al. Clinical study on the treatment of cancer-related fatigue in breast cancer patients with acupuncture. *Jiangsu J Traditional Chin Med.* (2016) 48(12):56–8.

or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1583522/ full#supplementary-material

21. Chen M, Lei H, Zheng S, Wang J. Effects of acupuncture on analgesia and immune function in breast cancer patients during the perioperative period. *J Int Traditional Chin Med.* (2018) 40(1):22–5. doi: 10.3760/cma.j.issn.1673-4246.2018.01.006

22. Delian C. Observation on the Short-term Therapeutic Effect of Acupuncture Combined with TCM Syndrome Differentiation and Chemotherapy in the Treatment of Stage III b and IV NSCLC. Guangzhou, Guangdong Province, PRC: Guangzhou University of Chinese Medicine (2008).

23. Yunqian G. Observation on the Therapeutic Effect of the Method of Consolidating the Root and Clearing the Source by Acupuncture on Gastric Cancer Patients Undergoing DCF Chemotherapy. Ji'nan, Shandong Province, PRC: Shandong University of Traditional Chinese Medicine (2013).

24. Shuai J, Ting W, Guohong W. Effects of acupuncture and moxibustion combined with chemoradiotherapy on nasopharyngeal carcinoma and their impact on VEGF, TGF- β 1 and immune function in patients. *Gen Pract Clin Educ.* (2020) 18(01):24–27 +31. doi: 10.13558/j.cnki.issn1672-3686.2020.001.006

25. Xing L. Clinical Study on the Effects of Ginger-separated Moxibustion on Cellular Immunity and Quality of Life in Chemotherapy Patients. Guangzhou, Guangdong Province, PRC: Guangzhou University of Chinese Medicine (2009).

26. Li D, Yu J, Li R, Sun X, Wang A. Analysis of the effects of warm acupuncture on gastrointestinal reactions and immune function in patients with advanced non-small cell lung cancer undergoing chemotherapy. *Chin Med Innovation*. (2020) 17(04):142–6. doi: 10.3969/j.issn.1674-4985.2020.04.036

27. Liao G, Long S, Deng H, Li Q, Huang J, Gan Z, et al. Clinical study on the detoxification effect of spiral acupuncture on platinum-based chemotherapy regimens for Malignant tumors. *Chin Med Herald.* (2018) 15(19):117–20.

28. Wei L. Clinical Research on the Treatment of Chemotherapy-Related Thrombocytopenia in Tumors with Warm Acupuncture on Back-Shu Points. Hefei, Anhui Province, PRC: Anhui University of Chinese Medicine (2022).

29. Jinfeng M. The Impact of Grain-Size Moxibustion on Zusanli (ST 36) on the Quality of Life and Immune Function of Patients with Non-Small Cell Lung Cancer. Nanjing, Jiangsu Province, PRC: Nanjing University of Chinese Medicine (2022).

30. Pan C, Xue H, Shen K, Zhang H, Zhou H, Hu B, et al. Research on the improvement of immune function and quality of life in gastric cancer patients by moxibustion. *Shanghai J Acupuncture Moxibustion*. (2013) 32(09):726–8. doi: 10.3969/j.issn.1005-0957.2013.09.726

31. Wenyia P. Research on the Effects of Fire Needle at Sifahua Points on Patients with Non-Small Cell Lung Cancer Undergoing Chemotherapy Based on Th1/Th2 and MMPs/TIMPs. Guangzhou, Guangdong Province, PRC: Guangzhou University of Chinese Medicine (2016).

32. Xiaoyan Q. Clinical Research on the Treatment of Cancer-Related Fatigue with Warm Moxibustion. Guangzhou, Guangdong Province, PRC: Guangzhou University of Chinese Medicine (2012).

33. Wang X, Fang H, Wang Y, Wang H. The effect of electroacupuncture on immune function in patients with advanced non-small cell lung cancer undergoing palliative Chemotherapy. *Modern Pract Med.* (2016) 28(08):1009–11. doi: 10.3969/j.issn.1671-0800.2016.08.016

34. Jing W. Clinical Research on the Treatment of Cancer-Related Fatigue in Patients with Non-Small Cell Lung Cancer After Chemotherapy with Warm Acupuncture. Shijiazhuang, Hebei Province, PRC: Hubei University of Chinese Medicine (2023).

35. Shuang W. Clinical Observation on the Prevention and Treatment of Radiation-Induced Lung Injury in Esophageal Cancer Patients After Radiotherapy with Leiho Moxibustion. Nanjing, Jiangsu Province, PRC: Nanjing University of Chinese Medicine (2016).

36. Xiaomin W. Clinical efficacy analysis of acupuncture and moxibustion in treating leukopenia after chemotherapy for Malignant tumors. *Dis Surveillance Control.* (2021) 15(03):207–9. doi: 10.19891/j.issn1673-9388.(2021)03-0207-03

37. Jun W. Observation on the therapeutic effect of tiaoyi sanjiao acupuncture and moxibustion on cancer-related fatigue in advanced non-small cell lung cancer and its impact on lymphocyte count. *J Traditional Chin Med External Therapies*. (2022) 31(02):96–8. doi: 10.3969/j.issn.1006-978X.2022.02.043

38. Tingting X, Dan W. Analysis of the effect of warm acupuncture combined with weishu capsules on gastrointestinal Malignant tumors. *Med Theory Pract.* (2022) 35(03):426–8. doi: 10.19381/j.issn.1001-7585.2022.03.026

39. Xing R, Yang Y, Zhang M, Wang H, Tan M, Gao C, et al. Effect of transcutaneous electrical acupoint stimulation combined with transversus abdominis plane block on postoperative recovery in elderly patients undergoing laparoscopic gastric cancer surgery: A randomized controlled trial. *Pain Ther.* (2022) 11(4):1327–39. doi: 10.1007/s40122-022-00429-2

40. Huisheng X, Qian L. The influence of acupuncture and moxibustion on TCM syndromes, quality of life and cellular immunity in patients with primary liver cancer undergoing transcatheter arterial chemoembolization. *Chin Community Doctor.* (2017) 33(30):108–109+111. doi: 10.3969/j.issn.1007-614x.2017.30.65

41. Yanlin X. The effect of fire needle at Sifahua points on IL-2, TNF-a and T cell subsets in lung cancer patients undergoing chemotherapy. Guangzhou, Guangdong Province, PRC: Guangzhou University of Chinese Medicine (2012).

42. Xu Q, Luo I, Wang H, Zeng C. The effect of acupuncture and moxibustion combined with radiotherapy and chemotherapy on local advanced cervical cancer and its influence on patients' immune function. *Contemp Med.* (2024) 30(13):6–10. doi: 10.3969/j.issn.1009-4393.2024.13.02

43. Haiyan X. The effect of mild moxibustion at Zusanli on the immune function of patients with gastric cancer. *Shanghai Nurs.* (2013) 13(05):29–32. doi: 10.3969/j.issn.1009-8399.2013.05.007

44. Fan Y. Clinical research on the treatment of cancer-related fatigue in colorectal cancer patients with warm acupuncture and moxibustion. Hefei, Anhui Province, PRC: Anhui University of Chinese Medicine (2021).

45. Shuangyan Z, Yeqin D. The effect of warm acupuncture and moxibustion on gastrointestinal function and immune function in patients after colorectal cancer surgery. *Chin Acupuncture Moxibustion.* (2011) 31(06):513–7. doi: 10.13703/j.0255-2930.2011.06.013

46. Bin Z. Clinical observation on the effect of Yang-strengthening and tonifying moxibustion on T lymphocyte subsets and quality of life in patients with advanced NSCLC. Jinzhong, Shanxi Province, PRC: Shanxi University of Chinese Medicine (2017).

47. Jinmei Z, Guojun Z, Yingying L. The promoting effect of warm acupuncture and moxibustion nursing pathway on rapid recovery in patients undergoing lung cancer surgery. *Tianjin J Traditional Chin Med.* (2021) 38(05):638–41. doi: 10.11656/j.issn.1672-1519.2021.05.20

48. Zhao X, Qiao S, Liu X, Tong Y, Yan H, Liu H, et al. The effect of Xihuang Pill combined with acupuncture and moxibustion on immune function and quality of life in patients with non-small cell lung cancer. *World J Chin Med.* (2022) 17(14):2021–5. doi: 10.3969/j.issn.1673-7202.2022.14.012

49. Gaofei Z. Clinical observation on the effect of Sanjiao acupuncture in improving cancer-related fatigue (Qi and blood deficiency type) in lung cancer patients. Tianjin, PRC: Tianjin University of Traditional Chinese Medicine (2023).

50. Zhou T, Li W, Yu J, Jia Y. The effect of moxibustion at Zusanli on the quality of life of patients with advanced Malignant tumors. *Chin Acupuncture Moxibustion*. (2019) 39(02):133-136+146. doi: 10.13703/j.0255-2930.2019.02.005

51. Li Z, Tianlong H, Jinfeng J. The effect of warm acupuncture and moxibustion combined with conventional gastrointestinal decompression on intestinal obstruction during the chemotherapy interval after abdominal tumor surgery and its influence on immune function. *Sichuan J Traditional Chin Med.* (2023) 41(04):195–8. doi: 10.3969/j.issn.1000-3649.2023.4.sczy202304054

52. Quinn S, Lenart N, Dronzek V, Scurti G, Hossain NM, Nishimura MI, et al. Genetic modification of T cells for the immunotherapy of cancer. *Vaccines.* (2022) 10 (3):10. doi: 10.3390/vaccines10030457

53. Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, et al. CD4+ T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy. *Cancer Immunol Res.* (2020) 8(3):334–44. doi: 10.1158/2326-6066.CIR-19-0574

54. Zhang Z, Zhang S, Xu Y, Liu X, Dong W. The differences in the distribution characteristics and prognostic value of tumor-infiltrating T lymphocyte subsets between lung adenocarcinoma and lung squamous cell carcinoma. *Chin Clin Oncol.* (2024) 13(6):83. doi: 10.21037/cco-24-62

55. Yang B, Li Z, Li P, Liang B, Liu YH, Feng ES, et al. Role of T cell metabolism in brain tumor development: a genetic and metabolic approach. *BMC Neurol.* (2025) 25 (1):12. doi: 10.1186/s12883-024-04015-1

56. Liu S, Meng Y, Liu L, Lv Y, Yu W, Liu T, et al. CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. *Cell Death Dis.* (2022) 13(5):441. doi: 10.1038/s41419-022-04882-x

57. Reina-Campos M, Scharping NE, Goldrath AW. CD8+ T cell metabolism in infection and cancer. *Nat Rev Immunol.* (2021) 21(11):718–38. doi: 10.1038/s41577-021-00537-8

58. Salih MM, Almehmadi M, Shafie A, Alsharif A, Alsiwiehri N, El-Askary A, et al. Evaluation of CD4+:CD8+ Ratio in patients with cervical cancer and the levels of inflammatory markers. *In Vivo*. (2022) 36(5):2414–21. doi: 10.21873/invivo.12975

59. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. *Nature*. (2009) 457(7229):557–61. doi: 10.1038/nature07665

60. Wu M, Lou J, Zhang S, Chen X, Huang L, Sun R, et al. Gene expression profiling of CD8+ T cells induced by ovarian cancer cells suggests a possible mechanism for CD8+ Treg cell production. *Cell Prolif.* (2016) 49(6):669–77. doi: 10.1111/cpr.2016.49.issue-6

61. Zhang X, Jing J. Effect of peripheral blood lymphocytes on prognosis of multiple cancers. *Cancer Control.* (2023) 30:10732748231202921. doi: 10.1177/10732748231202921

62. Ramzan M, Sturm N, Decaens T, Bioulac-Sage P, Bancel B, Merle P, et al. Liverinfiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. *Liver Int*. (2016) 36(3):434–44. doi: 10.1111/ liv.2016.36.issue-3

63. Yuan C, Huang J, Li H, Zhai R, Zhai J, Fang X, et al. Association of clinical outcomes and the predictive value of T lymphocyte subsets within colorectal cancer patients. *Front Surg.* (2023) 10:1102545. doi: 10.3389/fsurg.2023.1102545

64. Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. *Cell.* (2020) 183(2):363–76. doi: 10.1016/j.cell.2020.09.001

65. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. *Nat Med.* (2018) 24(2):144–53. doi: 10.1038/nm.4466

66. Poschke I, De Boniface J, Mao Y, Kiessling R. Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. *Int J Cancer*. (2012) 131(7):1611–20. doi: 10.1002/ijc.v131.7

67. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. *Curr Opin Immunol.* (2010) 22(2):223–30. doi: 10.1016/j.coi.2010.02.005

68. Zebley CC, Zehn D, Gottschalk S, Chi H. T cell dysfunction and therapeutic intervention in cancer. Nat Immunol. (2024) 25(8):1344–54. doi: 10.1038/s41590-024-01896-9

69. Sun LN, Su YH, Jiao AJ, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. (2023) 8(1):235. doi: 10.1038/s41392-023-01471-y

70. Zhai Y, Liang X, Deng M. Myeloid cells meet CD8+ T cell exhaustion in cancer: What, why and how. *Chin J Cancer Res.* (2024) 36(6):616–51. doi: 10.21147/j.issn.1000-9604.2024.06.04

71. Chen Y, Xu J, Wu X, Yao H, Yan Z, Guo, et al. CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape. *Cell Mol Immunol.* (2021) 18 (8):1995–2009. doi: 10.1038/s41423-020-00570-y

72. Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM, et al. Treg(s) in cancer: friends or foe? J Cell Physiol. (2015) 230(11):2598–605. doi: 10.1002/jcp.25016

73. Yan Y, Wang X, Liu C, Jia J. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study. *BMC Pulm Med.* (2022) 22(1):166. doi: 10.1186/s12890-022-01951-x

74. Laha D, Grant R, Mishra P, Nilubol N. The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment. *Front Immunol.* (2021) 12:656908. doi: 10.3389/fimmu.2021.656908